Breathing Labs
Home
How To Start
Products
Breathing+ Package
Toys Package
Q&A
Login
28Apr

COVID-19 headlining Reading Festival.

Posted by: admin Categories: PULMONARY DISEASES
Comments Off on COVID-19 headlining Reading Festival.

Festival organisers have confirmed that coronavirus, after a busy world tour, will be on the main stage at Reading and on pretty much everything else. Although it will be a short appearance, the impact of the concert could last a lifetime – which might be up to a few days.

Fans are looking forward to breathing in the atmosphere and then spending time in hospital. Known for their hit song ‘My Corona’, the band also does a series of Police covers; including ‘Every breath you take, Every sneeze you make’, ‘So Lonely, under House Quarantine’ and ‘Don’t stand so close me – really, Please Don’t.’

Said one excited fan of old-school influenza: ‘The great thing about seeing the band, is that you have wonderful sight-lines no matter where you are. In the portaloo, by the breakfast tent - COVID-19 is everywhere. It’s like you can reach out and touch it – without the hand gel. It’s like your own personal concert, with non-stop vomiting and diahorrea– a bit like when Oasis played’.

Coronavirus’ set is usually followed by a standing ovation and then three weeks lying in bed. For those who cannot afford to get tickets, not worry, COVID-19 is coming soon to an arena/bedroom near you.

If you enjoyed this archive item, why not buy thousands of archive stories found in our eBooks, paperbacks and hardbacks?

Source link

Tags:
28Apr

Prevention is key. Get vaccinated.

Posted by: admin Categories: PREVENTION & WELLBEING
Comments Off on Prevention is key. Get vaccinated.

Mary Bullard
 |  Community Columnist

During a rally in Richmond, Virginia, Donald Trump made his usual number of wild statements. One of his most dangerous comments didn’t get media attention: “I will not give one penny to any school that has a vaccine mandate or a mask mandate,” Trump declared. He promised to take all federal funds away from public schools that require vaccines like MMR, chickenpox vaccine, and polio vaccines. On Capitol Hill and across multiple states some GOP officials have begun condemning vaccine mandates — not just related to COVID-19, but all vaccines.

A little history: During the 1950s measles, mumps, chicken pox as well as coughs, sniffles and flu were accepted as an inevitable part of childhood. I shared a bedroom with my three younger siblings, so we had chicken pox sequestered together in a darkened room with mittens on so we wouldn’t scratch. We shared colds slathered in Vicks vapor rub, breathing steam from a bowl of heated water.

Measles is highly transmittable as the virus lingers in the air for hours. We, of course, shared this potentially fatal virus. When my younger brother’s fever spiked, my mother in the middle of the night wrapped him in a blanket and ran to the hospital that was next door to our apartment. They refused to treat him as he was infectious. My mother was handed a wooden tongue depressor, and a cab was called to take him to Detroit Children’s Hospital. He had developed encephalitis, a measles complication. Bruce was left handicapped, and after many months in rehabilitation and years of special care, my parents were left with medical bills that took years to pay off.

Before the 1963 vaccine development, measles caused an estimated 3 to 4 million cases each year, Additionally, measles caused ear infections, diarrhea, pneumonia, and encephalitis (swelling of the brain) that results in convulsions, deafness, or intellectual disability.

Measles was declared eliminated from the United States in 2000, thanks to a highly effective vaccination program and other control measures. A single dose of the vaccine is 93% effective at preventing measles; two doses are about 97% effective. Even today 1 in 5 unvaccinated people with measles is hospitalized. And among children, 1 in 20 gets pneumonia, which is the most common cause of death from measles in young children.

Why is this information important: Recently potentially hundreds of people were exposed to measles in Wayne and Washtenaw counties. As you don’t actually need to share the same airspace with an infected person at the same time, the risk is hidden. Measles can be contagious but asymptomatic for four days.

Prevention is key. Measles can be dangerous, but that’s especially true for unvaccinated children, pregnant women as well as people with compromised immune systems, such as those undergoing cancer treatment and people with HIV. Health leaders are calling on all Michiganders who can get the measles, mumps, rubella vaccine to ensure they have had two doses and are fully immunized.

Vaccines including MMR (Measles, Mumps, Rubella) and Chickenpox protect not only children but adults. For example, the chickenpox virus will remain dormant in the sensory nerve ganglia of the body. In adults over 50 years old who have had chickenpox, the virus can reactivate as Shingles at any time. This painful rash can cause complications including vision loss, balance or hearing issues, and often long-lasting pain at the site of the shingles rash. The vaccine is 90% effective in preventing Shingles in adults 50 years and older and is usually covered through insurance plans.

Vaccination mandates "are an American tradition," with roots that predate the United States itself. In fact, vaccines against smallpox during the Revolutionary War may have saved the Continental Army from defeat. Vaccination policies are common in schools nationwide. Students are required to receive mandated vaccinations before they can attend classes to protect themselves and others.

Vaccines protect those with health risks and fragile immune systems. They also protect young children and communities of color who are hit hard by disease. Immunizations protect not only yourself but those you care about.

— Mary Bullard is member of the Stronger Together Huddle, a group engaged in promoting and supporting the common good. She’s is a former librarian and lives in Temperance.

Source link

Tags:
27Mar

Can you go to work with Covid?

Posted by: admin Categories: PULMONARY DISEASES
Comments Off on Can you go to work with Covid?

(Getty/iStockphoto)

(Getty/iStockphoto)

Ever since the British government ended all legal Covid-19 restrictions earlier this year, cases numbers have continued to fluctuate.

Even as former prime minister Boris Johnson published his Living with Covid plan in February, ending mandatory masks, social distancing and self-isolation measures, the arrival of the contagious Omicron BA.2 sub-variant quickly drove the infection rate up before it fell away in spring, a pattern of ebb and flow that has continued ever since.

While lockdowns and tiers may now seem a distant memory, the virus is very much still with us. Cases have begun to rise again, with warnings that Covid will once again put pressure on the NHS this winter.

The Living with Covid plan brought an end to the legal requirement for employees to tell their employers when they have tested positive for the virus and need to self-isolate. But with the threat from Covid still very real, is going to work when sick really such a good idea?

Can I go to work with Covid?

Yes, you can go to work even after testing positive for Covid and there is no legal obligation to tell your employer if you are infected.

However, workers are encouraged to follow the government’s guidance for people who become infected with the virus and self-isolate for seven days.

Do I have to test for Covid before going to work?

No, you don’t have to test for Covid before going anywhere, including to work.

Most people in England are no longer advised to get tested and can no longer get free lateral flow tests from the NHS unless you are one of a small number of people who are eligible.

Those who want to get tested must buy a Covid-19 test from pharmacies and other retailers.

What should I do if I feel unwell?

The government has set out guidance for people who have symptoms of a respiratory infection but have not taken a test for Covid-19, as well as for those who have taken a test and received a positive result.

Symptoms of common respiratory infections and Covid-19 include a continuous cough; high temperature or fever; loss of, or change in normal sense of taste or smell; shortness of breath; lack of energy; lack of appetite; headache; sore throat and stuffy or runny nose.

According to the Department for Health and Social Care, you should work from home if you can and avoid contact with other people if you are experiencing these symptoms.

It is especially important to avoid close contact with anyone you know who may be at higher risk of becoming seriously sick if they catch Covid-19.

If you must leave your home, you should wear a face covering and avoid crowded or poorly ventilated places.

If you receive a positive Covid-19 test, you are also advised to stay at home and avoid contact with other people for five days after the day you took your test.

However, you should avoid meeting people at higher risk of serious illness from Covid-19 for 10 days after the day you took your test.

Source link

Tags:
27Mar

Scientist, 27, who helped UK through Covid died after cycling into wall | UK News

Posted by: admin Categories: PULMONARY DISEASES
Comments Off on Scientist, 27, who helped UK through Covid died after cycling into wall | UK News


Susannah Boddie was on holiday near Lake Garda, Italy, when she suffered fatal head injuries after the crash
Susannah Boddie was on holiday near Lake Garda, Italy, when she suffered fatal head injuries after the crash

A government scientist who helped steer the UK through the Covid-19 pandemic was killed on an holiday after crashing her bike into a concrete wall.

Susannah Boddie was on holiday near Lake Garda, Italy, in August when she suffered fatal head injuries after the crash.

The 27-year-old from Nettlebed, Oxfordshire, biked down a steep trail in the mountains above Toscolano Maderno with her boyfriend before colliding into a concrete wall.

She was the lead health data scientist for 10 Downing Street’s science team.

Her boyfriend Robert Johnson said: ‘We were on the last day cycling. Everything was normal and we were cycling for about 30 minutes and it was mostly downhill.

‘We were following a GPS route that took us down a smaller, steeper road but nothing I wasn’t comfortable doing and nothing Susannah hadn’t done before.

‘I was slightly ahead and suddenly she came flying past me and seemed out of control. She went around a bend ahead of me, out of sight.’

When he caught up with Susannah he could see she had crashed into a wall and appeared to be breathing but was bleeding from her mouth.


Susannah Boddie
She was the lead health data scientist for 10 Downing Street’s science team (Picture: Linkedin)

A passing couple stopped to help and emergency services arrived 30 minutes later due to the rural location, the inquest was told.

After 45 minutes of treatment, she was pronounced dead.

The inquest heard Susannah’s family had her bike, which she took to Italy herself, examined and it was considered a possibility the inner tube of the front wheel had exploded, rendering the brakes useless.

It was heard the bike had been fine the day before when the couple had been taking downhill routes.


lake garda death Susannah Boddie Lead Health Data scientist at Number 10, Downing Street
Susannah was described as an ‘inspiring woman’ (Picture: Facebook)

Coroner Darren Salter said that it was difficult to know what the circumstances were that has caused Susannah to lose control.

He said: ‘I’m not entirely sure if we will get to the bottom of what went wrong.’

After concluding an accidental death, Mr Salter said: ‘Susannah was an inspiring woman, an incredible scientist and was loved and admired by all. She had achieved so much in her short life.’

Get in touch with our news team by emailing us at [email protected].

For more stories like this, check our news page.



Source link

Tags:
27Mar

Swedish study suggests link between long COVID and severity of illness

Posted by: admin Categories: PULMONARY DISEASES
Comments Off on Swedish study suggests link between long COVID and severity of illness

SARS-CoV-2
NIAID

The global SARS-CoV-2 reinfection rate was just under 1% as of a year ago, with significant differences by variant, country, and time, according to a meta-analysis of 55 studies on more than 111,000 cases.

Published in BMC Infectious Diseases, the meta-regression analysis by Sichuan University researchers in China included 46 cohort, 6 case-control, and 3 cross-sectional studies on COVID-19 reinfection rates up to March 2023. Reinfections were considered those identified more than 90 days after a primary case. Possible resurgences or vaccine breakthrough infections were not included.

"Reinfections have been reported continuously since the first wave of the COVID-19 epidemic, and especially after the Omicron variant became a major prevalent variant worldwide, there has been a significant increase in the number of reported SARS-CoV-2 reinfections globally," the researchers wrote.

Reinfection rate highest during Omicron

Overall, the COVID-19 reinfection ranged from 0% to 28.4%, and the pooled reinfection rate was 0.9%. There were statistically significant rate differences by variant: 0.3% for the wild-type virus, 0.6% for the Alpha variant, 0.4% for Delta, and 4.1% for Omicron.

Reinfections have been reported continuously since the first wave of the COVID-19 epidemic, and especially after the Omicron variant became a major prevalent variant worldwide.

Brazil had the highest reinfection rate (6.6%), while Spain's rate was 0.3%. The rate varied over time, with the first notable change on day 154 (1.1%). The highest rate occurred on day 361 (2.9%). The US SARS-CoV-2 reinfection rate peaked at 0.2% on day 167.

While the second wave peak was lower than that in the first, the third wave peak was significantly higher. "We speculated that one of the reasons why the third peak was higher than the first peak might be caused by the weakening of the population’s immunity level over time," the authors wrote. "This phenomenon might be due to the fact that immunization levels decreased over time after vaccination or infection with SARS-CoV-2."

"Our results warn us that the natural decay of immune levels over time may lead to the reinfection of SARS-CoV-2, resulting in a new round of COVID-19 pandemic," they added.

Source link

Tags:
27Mar

“I had a panic attack, I felt like I was being a drama queen”: Harrowing experience on Indian Wells return told by Kim Clijsters

Posted by: admin Categories: ANXIETY MANAGEMENT
Comments Off on “I had a panic attack, I felt like I was being a drama queen”: Harrowing experience on Indian Wells return told by Kim Clijsters

The former
world No. 1 Kim Clijsters commented on a panic attack she experienced in the
2021 Indian Wells. The Belgian returned to tennis for the second time in 2020
after 7 years since her retirement and played two tournaments in the Dubai Open
and Monterrey Open, but her comeback was halted when the Covid-19 pandemic
forced the cancellation of tournaments between March and July of that year.

After the
pandemic, she barely played a couple of matches before contracting COVID-19,
which once again kept her off the courts. In October 2021, Clijsters
participated in Indian Wells, which was postponed from March to October, and
was eliminated in the first round against Katerina Siniakova.

The 4-times
Grand Slam champion was invited to the program "Served with Andy
Roddick" and commented that she experienced a panic attack for the first
time while preparing to participate in Indian Wells.

"I
remember hitting with Kiki Bertens and Ajla Tomljanovic and I had such good
practices, be it practice sets, be it beating girls in practice, but I just
wanted to kind of prove it in a match,” the former world No. 1 started.

“And during
one of the practices I just started like, yeah, really I had a panic attack on
the tennis court. For a second, I felt like I was being a drama queen,"
Clijsters added.

"My
trainer was like 'Just lay down, put your legs up', and that, like, me calming
down, or that wasn't working at all. So I was like, to my tennis coach, 'Go
stand at the net and hit towards me'. So I had the rhythm and the sound of the
ball, and my breathing rhythm came back," she concluded.

=https://twitter.com/TennisChannel/status/1446261891706281985" data-service="twitter">



Source link

Tags:
27Mar

Are long COVID sufferers falling through the cracks?

Posted by: admin Categories: PULMONARY DISEASES
Comments Off on Are long COVID sufferers falling through the cracks?

Researchers who study long COVID say its debilitating symptoms are often misdiagnosed by clinicians and dismissed by employers or loved ones because so little is known about the new syndrome. The results can be devastating for individuals and their families -- and for the economy.

It reminds Stanford Medicine's Hector Bonilla, MD, of another little-understood condition that the medical world still struggles to treat correctly.

"I've been working on chronic fatigue syndrome for almost eight years; when long COVID came along it was like déjà vu," said Bonilla, a clinical associate professor and an infectious disease physician who is a co-director of the Stanford Post-Acute COVID-19 Syndrome Clinic. "This is nothing new. We've been ignoring these problem for decades -- so it's time to pay attention."

Hector Bonilla

Nearly 1.2 million people have died from COVID-19, accounting for 2.2% of all deaths since the pandemic began, according to the Centers for Disease Control and Prevention. The CDC believes at least 5,000 people have died from long COVID, but it is trying to get a better account by issuing new autopsy guidelines for reporting long COVID as the cause of death.

Today, an estimated 16 million working-age people have long COVID, 4 million of whom can't work due to the debilitating symptoms. One of the worst things a long COVID patient can hear from their primary care physician, said Bonilla, is that they just need more sleep and to improve their diet and exercise. This attitude, he said, recalls the early days of CFS, when more physical activity was a common recommendation.

Long COVID and chronic fatigue syndrome symptoms are similar: severe exhaustion, brain fog, chest pain, coughing and difficulty breathing. Some patients experience cardiac and gastrointestinal issues, as well as loss of taste and smell and elevated levels of depression and anxiety.

Bonilla was joined recently by Gopi Shah Goda, PhD, a health economist who is a senior fellow at the Stanford Institute for Economic Policy Research. While she is researching the economic impact of the syndrome, Bonilla is focused on helping patients and letting them know they are not alone.

"You have to validate them," Bonilla said. "You have to say, 'Yes, I hear you and you are not alone; there are millions of people with the same problems you're having.'"

He said he's seen patients who have lost their homes and are living out of their cars, couples who are divorcing because one spouse doesn't believe the other is truly sick.

The economic impact

Goda calculates that on top of the quarter-million people of working age who died from COVID-19, at least twice that number have disappeared from the workforce. In a study published by the Journal of Public Economics, Goda estimates the average individual earnings loss due to long COVID-19 is $9,000 and the total lost labor supply has amounted to $62 billion annually.

Gopi Shah Goda

That's nearly half of the estimated productivity losses from cancer or diabetes. Yet, the Stanford experts say, those diseases receive billions of research dollars annually while long COVID research remains woefully underfunded.

"If you think about the budgets for some of the parts of the NIH [National Institutes of Health] that are funding research on cancer and diabetes, it's in the billions, and the amount that has been invested in long COVID is more in the millions," Goda said.

Stanford's long COVID clinic, which opened in May of 2021, received a grant last year of $1 million annually for five years from the U.S. Department of Health and Human Services to expand access to care for people with long COVID -- particularly those from underserved, rural, vulnerable and minority populations that were disproportionately impacted by the pandemic.

Goda believes many long COVID sufferers are falling through the cracks because clinicians aren't certain how to categorize their illnesses, so workers could be losing out on disability insurance through their employers or Social Security Disability Insurance.

The COVID-19 public health emergency expired in May 2023, and the CDC earlier this month lifted the five-day isolation guidance for those who test positive for COVID-19. Both Bonilla and Goda said they hoped this would not lead to relaxations that make workers more vulnerable, particularly those who have no access to paid leave.

No approved treatment but hope on horizon

Experts say 37% of COVID survivors report having at least one long COVID symptom in the 90 to 180 days after their initial infection.

But like chronic fatigue syndrome, there are no tests or approved treatments for long COVID, though Bonilla said he's seeing some positive results in his clinic by treating patients with off-label, low-dose naltrexone -- a pain reliever and anti-inflammatory -- and low doses of the antipsychotic drug Abilify.

There are also efforts to raise awareness about the need for more research that could lead to a cure. March 15 marked the second annual Long COVID Awareness Day, and the NIH is eager to get people with long COVID to join its CureID  research program.

In addition, the U.S. Senate Committee on Health, Education, Labor and Pensions held a hearing in January on long COVID, with committee chair Sen. Bernie Sanders (I-Vermont) acknowledging that Congress needs to do more.

"There's a sense that something is going on in America which is serious that we're not addressing," Sanders said. "So I just want to say to our panelists and all those who are dealing with long COVID: We hear you what you're experiencing, and we take it seriously. We think we Congress has not done anywhere near enough, and we hope to turn that around."

Goda submitted a statement to the committee for that hearing, emphasizing the need for more mitigation policies and programs to help workers remain in the workforce.

More news on long COVID

"Despite COVID's harmful impact on the U.S. workforce overall, there are some signs of good news," she said in her statement. "So far, employment and labor force participation rates increased faster among those who report having a disability, likely because of new opportunities to work from home and the tight labor markets."

She noted there are also lower rates of COVID-19 related work absences. Between January and October of 2023, likely COVID-19 related absences from work were 16% higher than pre-pandemic levels. This was a sharp drop from 61% during March 2020 through December 2022.

Still, Bonilla said, while long-COVID may be getting more national recognition, many patients don't have access to health care or live far from clinics, such as native Americans, those in rural communities, and undocumented workers.

"There are people who have no voice, and nobody is talking about them," he said.

Beth Duff-Brown is the communications manager for Stanford Health Policy

Image: Donkeyworx

Source link

Tags:
27Mar

Inhaled Nitric Oxide Market Projected to Reach $1,157.38 million by 2030

Posted by: admin Categories: PULMONARY DISEASES
Comments Off on Inhaled Nitric Oxide Market Projected to Reach $1,157.38 million by 2030

PUNE, India, March 27, 2024 /PRNewswire/ -- The report titled "Inhaled Nitric Oxide Market by Application (Acute Respiratory Distress Syndrome, Chronic Obstructive Pulmonary Disease, Malaria Treatment), End-Users (Clinic, Hospital) - Global Forecast 2024-2030" is now available on 360iResearch.com's offering, presents an analysis indicating that the market projected to grow from a size of $778.21 million in 2023 to reach $1,157.38 million by 2030, at a CAGR of 5.83% over the forecast period.

360 iResearch Logo360 iResearch Logo

360 iResearch Logo

"Expanding Boundaries Revolutionizing Respiratory Care Using Inhaled Nitric Oxide Globally"

Using inhaled nitric oxide in intensive care is a significant therapy, primarily benefiting newborns and children suffering from severe pulmonary conditions such as persistent pulmonary hypertension of the newborn (PPHN) and acute respiratory distress syndrome (ARDS). This innovative treatment, delivered directly to the lungs, effectively enhances oxygenation without influencing blood pressure elsewhere, marking a significant stride in medical care. Its application has broadened beyond hospital settings to include home care, thereby promising a better quality of life for patients as the incidence of conditions treated by inhaled nitric oxide rises with technological advancements in portable delivery systems. Nonetheless, the market faces challenges due to the high costs and rigorous regulatory standards governing its use. The continued research into new therapeutic uses and improvements in delivery technology are setting the stage for more accessible and cost-effective treatments. Globally, inhaled nitric oxide is gaining traction, especially in the Americas, driven by a high rate of respiratory illnesses and a robust healthcare infrastructure. Europe is witnessing a growing demand, backed by innovation and robust regulatory frameworks, whereas the Asia-Pacific region is rapidly adopting this therapy, fueled by healthcare advancements and an increasing awareness of cutting-edge treatments.

Download Sample Report @ www.360iresearch.com/library/intelligence/inhaled-nitric-oxide

"Enhancing Respiratory Care: The Increasing Role of Inhaled Nitric Oxide Amid Rising Respiratory Disorders"

The medical community is turning toward innovative treatments such as inhaled nitric oxide (iNO)owing to the global increase in respiratory diseases, such as chronic obstructive pulmonary disease (COPD), the ongoing impacts of conditions such as acute respiratory distress syndrome (ARDS), and the long-term effects of COVID-19. Renowned for improving oxygenation in the lungs through vasodilation, iNO therapy is a groundbreaking solution in treating various respiratory issues, including pulmonary hypertension and ARDS. Its role in enhancing lung function while reducing reliance on mechanical ventilation is particularly notable in neonatal care, where it offers hope for premature infants facing hypoxic respiratory failure. The adoption of iNO in healthcare settings is gaining pace as respiratory disorders continue to affect millions globally due to respiratory illness. This treatment's integration into patient care routines highlights a critical advancement in addressing the urgent need for effective, non-invasive therapies, driving improvements in respiratory health and patient recovery rates.

"Revolutionizing Respiratory Care: The Expanding Role of Inhaled Nitric Oxide"

Inhaled nitric oxide (iNO) is a treatment crucial in managing various respiratory conditions by enhancing oxygenation and easing pulmonary arterial pressures. Its capability to dilate lung blood vessels offers significant benefits, particularly for chronic obstructive pulmonary disease (COPD) patients. These individuals often face severe flare-ups that worsen their breathing difficulties. iNO offers expectancy during critical times, potentially improving gas exchange and lessening the effects of pulmonary hypertension. Emerging research highlights iNO's potential in combating severe malaria, owing to its inflammation-reducing capabilities and improvement in blood flow. Furthermore, its established success in treating newborns with hypoxic respiratory failure highlights its life-saving impact. Additionally, exploring iNO in treating tuberculosis opens a new frontier, especially for combating drug-resistant strains, showcasing its versatility and potential as an adjunctive therapy. This multipurpose application of inhaled nitric oxide highlights its pivotal role in advancing respiratory care and offering hope to patients across a spectrum of conditions.

Request Analyst Support @ www.360iresearch.com/library/intelligence/inhaled-nitric-oxide

"Merck KGaA at the Forefront of Inhaled Nitric Oxide Market with a Strong 11.95% Market Share"

The key players in the Inhaled Nitric Oxide Market include VERO Biotech Inc., Getinge AB, Air Liquide SA, Merck KGaA, GE HealthCare Technologies, Inc., and others. These prominent players focus on strategies such as expansions, acquisitions, joint ventures, and developing new products to strengthen their market positions.

"Introducing ThinkMi: Revolutionizing Market Intelligence with AI-Powered Insights for the Inhaled Nitric Oxide Market"

We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Inhaled Nitric Oxide Market. ThinkMi stands out as your premier market intelligence partner, delivering unparalleled insights with the power of artificial intelligence. Whether deciphering market trends or offering actionable intelligence, ThinkMi is engineered to provide precise, relevant answers to your most critical business questions. This revolutionary tool is more than just an information source; it's a strategic asset that empowers your decision-making with up-to-the-minute data, ensuring you stay ahead in the fiercely competitive Inhaled Nitric Oxide Market. Embrace the future of market analysis with ThinkMi, where informed decisions lead to remarkable growth.

Ask Question to ThinkMi @ app.360iresearch.com/library/intelligence/inhaled-nitric-oxide

"Dive into the Inhaled Nitric Oxide Market Landscape: Explore 180 Pages of Insights, 198 Tables, and 20 Figures"

  1. Preface

  2. Research Methodology

  3. Executive Summary

  4. Market Overview

  5. Market Insights

  6. Inhaled Nitric Oxide Market, by Application

  7. Inhaled Nitric Oxide Market, by End-Users

  8. Americas Inhaled Nitric Oxide Market

  9. Asia-Pacific Inhaled Nitric Oxide Market

  10. Europe, Middle East & Africa Inhaled Nitric Oxide Market

  11. Competitive Landscape

  12. Competitive Portfolio

Inquire Before Buying @ www.360iresearch.com/library/intelligence/inhaled-nitric-oxide

Related Reports:

  1. Inhaled Nitric Oxide Delivery Systems Market - Global Forecast 2024-2030

  2. Medical Nitrous Oxide Market - Global Forecast 2024-2030

  3. Concentrated Nitric Acid Market - Global Forecast 2024-2030

About 360iResearch

Founded in 2017, 360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.

We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset — our people.

Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.

Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.

Contact 360iResearch

Mr. Ketan Rohom
360iResearch Private Limited,
Office No. 519, Nyati Empress,
Opposite Phoenix Market City,
Vimannagar, Pune, Maharashtra,
India - 411014.
Email: [email protected]
USA: +1-530-264-8485
India: +91-922-607-7550

To learn more, visit 360iresearch.com or follow us on LinkedIn, Twitter, and Facebook.

Logo: mma.prnewswire.com/media/2359256/360iResearch_Logo.jpg

 

CisionCision

Cision

View original content:www.prnewswire.com/news-releases/inhaled-nitric-oxide-market-projected-to-reach-1-157-38-million-by-2030---exclusive-report-by-360iresearch-302101075.html

SOURCE 360iResearch



Source link

Tags:
27Mar

Respiratory Care Device Market Projected to Reach USD 38.55 Billion by 2030 Driven by CAGR of 8.9%

Posted by: admin Categories: PULMONARY DISEASES
Comments Off on Respiratory Care Device Market Projected to Reach USD 38.55 Billion by 2030 Driven by CAGR of 8.9%

The global respiratory care device market is poised for significant growth owing to the rising prevalence of respiratory diseases and increasing awareness about respiratory health.

The SNS Insider report indicates that the Respiratory Care Device Market Size was valued at USD 19.49 Billion in 2022 and is expected to reach USD 38.55 Billion by 2030, growing at a CAGR of 8.9% over the forecast period 2023-2030.

Market report Scope

Respiratory Care Devices are utilized for analysis, monitoring, and therapy of respiratory infections like Chronic Obstructive Pulmonary Disease (COPD), asthma, tuberculosis, and pneumonia. These devices provide improved care to patients experiencing such acute and chronic respiratory illnesses.

The report analyses the respiratory care devices market based on product type, end-user, and geography. As the world's population ages and environmental factors affect respiratory health, there is a growing demand for respiratory care equipment.

These medical supplies and apparatus help patients control respiratory conditions or provide breathing support when required. They are used in various healthcare settings, including clinics, hospitals, and home care settings.

Market Analysis:

Demand for respiratory care is driven by infectious respiratory diseases, which have increased during the pandemic, boosting the market. Government and non-profit initiatives like the global initiative for asthma (GINA) and awareness campaigns have also contributed to market growth.

Moreover, the increase in the geriatric population and the rising prevalence of respiratory diseases further accelerate market expansion.

Get Free Sample Copy of Report: www.snsinsider.com/sample-request/1072

Major Key Players in Respiratory Care Device Market:

  • Koninklijke Philips N.V.

  • ResMed

  • Medtronic

  • Fisher and Paykel Healthcare Limited

  • BD

  • Chart Industries Inc.

  • Drägerwerk

  • AG & Co. KGaA

  • Hamilton Medical

  • Teleflex Incorporated

  • 3M

Key Segments Covered in Report:

By Product:

  • Therapeutic Devices                

  • Monitoring Devices        

  • Diagnostic Devices

  • Consumables and Accessories

By Indication:

  • Chronic Obstructive Pulmonary Disease (COPD)             

  • Asthma              

  • Sleep Apnea

  • Infectious Disease        

  • Others

By End-User

  • Hospitals    

  • Home Care Settings

  • Ambulatory Care Centers

  • Others

Segment Analysis:

By disease indication, the COPD segment dominates due to factors such as tobacco smoking, indoor/outdoor air pollution, and exposure to dust and chemicals, which contribute to COPD's prevalence.

By end users, home care settings are witnessing rapid growth, especially in sleep apnea therapeutics, driven by the convenience they offer to patients.

Ask For Discount: www.snsinsider.com/discount/1072

Regional Development:

North America leads the respiratory care devices market due to the high prevalence of respiratory illnesses like COPD. In contrast, the Asia-Pacific region is growing significantly due to a large pool of respiratory patients, air pollution, and the rise in tobacco smoking.

Additionally, APAC's development as a medical tourism hub attracts patients due to lower costs and the availability of skilled medical professionals.

Key Takeaways:

The respiratory care device market is on a trajectory to reach USD 38.55 billion by 2030, fueled by rising respiratory diseases and increased awareness.

COPD and home care settings are dominant segments, driven by factors like tobacco smoking and patient convenience.

North America and Asia-Pacific lead in market size and growth, respectively, due to disease prevalence and healthcare infrastructure.

Recent Developments:

In July 2022, Smile Train, Inc. and Lifebox partnered to launch the Lifebox-Smile Train pulse oximeter, expanding access to critical care tools.

Omron Healthcare also introduced a portable oxygen concentrator, a breakthrough in oxygen therapy for continuous high-purity oxygen supply.

Respiratory Care Device Market Report: www.snsinsider.com/checkout/1072

Table of Content

Chapter 1 Introduction 

Chapter 2 Research Methodology

Chapter 3 Respiratory Care Device Market Dynamics

Chapter 4 Impact Analysis (COVID-19, Ukraine- Russia war, Ongoing Recession on Major Economies)

Chapter 5 Value Chain Analysis

Chapter 6 Porter’s 5 forces model

Chapter 7 PEST Analysis

Chapter 8 Respiratory Care Device Market Segmentation, By Product

Chapter 9 Respiratory Care Device Market Segmentation, By Indication

Chapter 10 Respiratory Care Device Market Segmentation, By End-User

Chapter 11 Regional Analysis

Chapter 12 Company profile

Chapter 13 Competitive Landscape

Chapter 14 Use Case and Best Practices

Chapter 15 Conclusion

News From

SNS Insider PVT LTDSNS Insider PVT LTD
Category: Industry Reports & Market Analysis Profile: In the fast-paced business biospheres, businesses need to constantly evolve to grow and stay relevant. At SNS Insider, we believe in adopting a data-oriented approach to aid organizations be familiar with the nerve of the industry.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Source link

Tags:
27Mar

Asthma Inhaler Market Booming at 6.42% CAGR to Reach $19.68

Posted by: admin Categories: PULMONARY DISEASES
Comments Off on Asthma Inhaler Market Booming at 6.42% CAGR to Reach $19.68

Asthma Inhaler Device Market

Asthma Inhaler Device Market

Market Overview

Based on the research findings, the Asthma Inhaler Device Market is anticipated to grow at a Compound Annual Growth Rate (CAGR) of 6.42% throughout the forecast period, reaching a revenue of USD 19,677.54 million by the end of 2030.

Asthma, a chronic lung condition, causes inflammation and narrowing of the airways, leading to symptoms such as coughing, chest tightness, difficulty breathing, and shortness of breath. Asthma inhaler devices, handheld devices, are crucial in managing these breathing difficulties by delivering medication directly to the airways, thereby treating or preventing associated diseases.

The report comprehensively covers the driving factors fueling market growth, shedding light on key players and their strategies to navigate the competitive landscape of the Asthma Inhaler Device Market. Furthermore, the report addresses the post-COVID-19 scenario of the market and provides insights into market segmentation and regional analysis.

Get Free Sample PDF Brochure: www.marketresearchfuture.com/sample_request/1653

Market dynamics

Drivers:

The Asthma Inhaler Device Market is poised for growth during the forecast period, primarily driven by the increasing prevalence of asthma worldwide. Rising cases of asthma, particularly among children, coupled with growing awareness among the general population, are fueling the demand for metered dose inhalers and other asthma inhaler devices. This surge in demand, alongside heightened awareness of asthma-related issues, is a key factor propelling market growth.

Opportunities:

The Asthma Inhaler Device Market presents numerous opportunities, with many prominent key players investing significantly in research and development activities. These investments, coupled with new product launches and collaborations among market players, are expected to create a multitude of opportunities within the market. Collaborative efforts and innovative product introductions not only enhance the competitiveness of the market but also expand the range of options available for asthma management, thereby driving growth and meeting the evolving needs of patients.

Competitive landscape

Major key players

GlaxoSmithKline plc (UK)

Koninklijke Philips NV (Netherlands)

AstraZeneca (UK)

Cipla Inc. (India)

Boehringer Ingelheim International GmbH (Germany)

Beximco Pharmaceuticals Ltd (Bangladesh)

Merck & Co., Inc. (the US)

Teva Pharmaceutical Industries Ltd (Israel)

Chiesi Farmaceutici SpA (Italy)

Medisol Lifescience Pvt. Ltd (India).

Buy Now Premium Research Report: www.marketresearchfuture.com/checkout?currency=one_user-USD&report_id=1653

Segmental Analysis:

The Asthma Inhaler Device Market offers a variety of inhaler options, including metered dose inhalers, dry powder inhalers, and soft mist inhalers. These inhaler devices come in both digitally and manually operated forms, catering to various preferences and needs. The market serves hospitals & clinics, homecare settings, and other end users.

Detailed Regional Analysis:

North America:Currently dominates the asthma inhaler device market due to the increasing prevalence of asthma, demand for cutting-edge technologies, and the popularity of metered-dose inhalers in the region. The region's robust healthcare system, easy access to medical care, and substantial disposable income contribute to market growth. Government support and funding for innovative asthma monitoring devices further drive market growth.

Asia Pacific:Expected to witness rapid growth during the forecast period, attributed to the rising prevalence of asthma and respiratory diseases, improvements in the healthcare system, and increased awareness regarding asthma symptom tracking and monitoring benefits. Countries like China, India, and South Korea, with rapidly growing economies and high asthma prevalence, are driving market expansion.

Europe:Anticipated to be the second-largest market, driven by healthcare authorities' initiatives to increase asthma awareness and improve asthma management.

Browse In-depth Market Research Report (124 Pages) on Asthma Inhaler Device: www.marketresearchfuture.com/reports/asthma-inhaler-device-market-1653

Competitive Analysis:

Innovation is expected to play a crucial role in the success of companies in the asthma inhaler device market. Factors such as the growing elderly population, increased awareness of respiratory disorders, rising disposable income, research and development efforts, and healthcare cost inflation positively impact market growth. Better distribution and commerce policies are expected to further boost market expansion. Mergers and acquisitions are likely to increase, with government organizations playing a crucial role in market growth. The market is poised for significant expansion in the coming years, driven by high asthma-related mortality rates and increased expenditures on asthma treatment. The presence of key market players and advancements in product technologies also contribute to market growth.

More Trending Reports:

Aesthetics Market - www.marketresearchfuture.com/reports/aesthetics-market-3136

Healthcare Cold Chain Logistics Market - www.marketresearchfuture.com/reports/healthcare-cold-chain-logistics-market-6550

Digital Healthcare Market - www.marketresearchfuture.com/reports/digital-healthcare-market-7636

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis regarding diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Contact

Market Research Future (Part of Wantstats Research and Media Private Limited)

99 Hudson Street, 5Th Floor

New York, NY 10013

United States of America

+1 628 258 0071 (US)

+44 2035 002 764 (UK)

Email: [email protected]

This release was published on openPR.

Source link

Tags:
27Mar

Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Posted by: admin Categories: PULMONARY DISEASES
Comments Off on Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

  • Announces next-generation COVID-19 vaccine candidate as fourth respiratory vaccine to successfully meet its Phase 3 endpoints
  • Expects two more Phase 3 readouts in 2024, including combination vaccine against flu and COVID-19, and vaccine against CMV
  • Announces positive clinical trial data from three new vaccines against viruses that cause significant burden (Epstein-Barr virus, Varicella-Zoster virus, norovirus) and advances programs toward Phase 3 development
  • Anticipates U.S. launch of vaccine against RSV following FDA approval and ACIP recommendation in 2024
  • Announces development and commercialization funding agreement with Blackstone Life Sciences for up to $750 million to advance flu program

CAMBRIDGE, MA / ACCESSWIRE / March 27, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced at its fifth Vaccines Day event clinical and program updates demonstrating advancement and acceleration of its mRNA pipeline. The updates include data readouts in the Company's respiratory and latent and other vaccine portfolios, as well as commercial, manufacturing and financial announcements for its vaccines business.

"Our mRNA platform continues a remarkable track record across our broad vaccine portfolio. Today, we are excited to share that four vaccines in our pipeline have achieved successful clinical readouts across our respiratory, latent and other virus franchises," said Stéphane Bancel, Chief Executive Officer of Moderna. "With five vaccines in Phase 3, and three more moving toward Phase 3, we have built a very large and diverse portfolio addressing significant unmet medical needs. We are focused on execution to further build momentum across our pipeline and business, and to deliver for patients who are impacted by these infectious diseases."

Portfolio Overview

The vaccine portfolio seeks to address infectious diseases that cause considerable health burdens and includes 28 vaccines addressing respiratory, latent and other pathogens.

Latent and Other Vaccine Portfolio

Moderna is advancing five vaccine candidates against viruses that cause latent infections, all of which are in clinical trials. When latent, a virus is present in the body but exists in a resting state, typically without causing any noticeable symptoms. Latent viruses can reactivate and cause clinical symptoms as a person ages, during times of stress or when immunity is compromised. The capacity for latency is a defining feature of members of the Herpesviridae family, including cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex virus (HSV) and Varicella-Zoster virus (VZV).

Cytomegalovirus (CMV)

CMV is the most common infectious cause of birth defects in the U.S. and is responsible for several billion dollars in annual healthcare costs. One in 200 babies in the U.S. are born with a congenital CMV infection, and of those affected, one in five will have severe, life-altering health problems. Possible short- and long-term sequelae of CMV infection include microcephaly, chorioretinitis, seizures, sensorineural hearing loss, cognitive impairment and cerebral palsy. There is currently no approved vaccine to prevent congenital CMV.

CMVictory is a pivotal Phase 3 trial evaluating mRNA-1647 against primary CMV infection in women 16 to 40 years of age. The trial is a randomized, observer-blind, placebo-controlled study designed to evaluate the efficacy, safety and immunogenicity of mRNA-1647. The trial is fully enrolled with approximately 7,300 participants from 290 clinical sites globally.

To date, 50 primary infection cases have accrued and are undergoing confirmation. The first interim analysis for the evaluation of vaccine efficacy, which will be triggered when both 81 confirmed per-protocol cases and 12 median months of safety follow-up have occurred, is expected as early as the end of 2024.

Moderna's CMV vaccine candidate mRNA-1647 has advanced to indication expansion studies in adolescents 9 to 15 years of age and adult transplant patients, both of which have begun enrollment.

Epstein-Barr virus (EBV)

EBV is a major cause of infectious mononucleosis (IM) in the U.S., accounting for more than 90% of IM cases annually. Importantly, EBV and IM are associated with a higher lifetime risk of more serious sequelae including certain cancers such as gastric carcinoma, nasopharyngeal carcinoma and multiple types of lymphoma. The lifetime risk of developing multiple sclerosis (MS) is increased by 32-fold after EBV infection. There is currently no approved vaccine to prevent EBV.

Moderna's EBV vaccine candidates are designed to tackle multiple EBV-associated conditions, including prevention of IM (mRNA-1189) and MS and post-transplant lymphoproliferative disorder, a subcategory of lymphoma in solid organ transplant patients (mRNA-1195). The Phase 1 trial for mRNA-1189 was designed to test the safety, reactogenicity and immunogenicity of four different dose levels in participants 12 to 30 years of age in the U.S. The randomized, observer-blind, placebo-controlled study showed mRNA-1189 was immunogenic and generally well tolerated across all dose levels. The Company is advancing mRNA-1189 toward a pivotal Phase 3 trial.

The Phase 1 trial for mRNA-1195 was designed to test the safety, reactogenicity and immunogenicity of two drug products at four different dose levels in healthy EBV seropositive participants 18 to 55 years of age in the U.S. The randomized, observer-blind, placebo-controlled study is fully enrolled.

Herpes simplex virus (HSV)

Herpes simplex virus type 2 (HSV-2) infects approximately 13% of adults globally and is the primary cause of genital herpes. There are an estimated four billion people globally infected with HSV, of which 491 million cases are HSV-2. Recurrent genital herpes causes a reduction in quality of life, which antivirals (current standard of care) only partially restore. Moderna expects that if an HSV vaccine candidate could deliver similar efficacy as a suppressive antiviral treatment, compliance with recommended therapy and associated quality of life would improve. There is currently no approved vaccine to treat HSV-2.

The first in human, fully enrolled Phase 1/2 trial of mRNA-1608 is designed to test safety and immunogenicity and to establish a proof-of-concept of clinical benefit in adults 18 to 55 years of age with recurrent HSV-2 genital herpes. The randomized 1:1:1:1, observer-blind, controlled study is fully enrolled with 300 participants in the U.S.

Varicella-Zoster virus (VZV)

Herpes zoster, also known as shingles, is caused by reactivation of latent VZV, the same virus that causes chickenpox. Declining immunity in older adults decreases immunity against VZV, allowing reactivation of the virus from latently infected neurons, causing painful and itchy lesions. Herpes Zoster occurs in one out of three adults in the U.S. in their lifetime and the incidence increases at 50 years of age. There is potential to reach a growing and underserved patient population.

Moderna's VZV vaccine candidate mRNA-1468 has initial data available from a Phase 1/2 trial, which was designed to test safety and immunogenicity in healthy adults 50 years of age and older in the U.S. The randomized 1:1:1:1:1, observer-blind, active-controlled study of mRNA-1468 elicited strong antigen-specific T cell responses at one month after the second dose and was generally well tolerated. Results of the first interim analysis support the further clinical development of mRNA-1468 for the prevention of shingles. Additional results from the ongoing Phase 1/2 study will be available later this year, including persistence data. The Company is planning for a pivotal Phase 3 trial.

Norovirus

Enteric viruses, including norovirus, are a leading cause of diarrheal diseases, resulting in significant morbidity and mortality worldwide, particularly among young children and older adults. Norovirus is highly contagious and a leading cause of diarrheal disease globally, associated with 18% of all acute gastroenteritis (AGE), resulting in approximately 200,000 deaths per year and substantial healthcare costs. Given the wide diversity of norovirus genotypes, a broadly effective norovirus vaccine will require a multivalent vaccine design. There is currently no approved vaccine to prevent norovirus.

The randomized, observer-blind, placebo-controlled Phase 1 trial was designed to evaluate the safety, reactogenicity and immunogenicity of trivalent (mRNA-1403) and pentavalent (mRNA-1405) norovirus vaccine candidates in 664 participants 18 to 49 years of age and 60 to 80 years of age in the U.S. An interim analysis showed that a single dose of mRNA-1403 elicited a robust immune response across all dose levels evaluated with a clinically acceptable reactogenicity and safety profile. The Company is advancing mRNA-1403 toward a pivotal Phase 3 trial.

Respiratory Vaccine Portfolio

Moderna's approach to ease the global burden of respiratory infections includes vaccine candidates against major causative pathogens, including SARS-CoV-2, respiratory syncytial virus (RSV) and influenza virus. Respiratory infections are a top cause of death in the U.S. and are particularly harmful to the young, immunocompromised, and older adults who experience more severe illness, greater incidence of hospitalization, and greater mortality than younger adults.

Moderna's respiratory pipeline includes Phase 3 trials for investigational vaccines including a next-generation COVID-19 vaccine, an RSV vaccine, a flu vaccine, and a flu and COVID-19 combination vaccine. The pipeline includes three additional flu vaccine candidates with expanded antigen coverage as well as combination vaccine programs.

COVID-19

Moderna continues to address the needs of the endemic COVID-19 market by focusing on public health efforts to increase vaccination coverage rates to reduce the substantial burden of COVID-19 as well as by advancing next-generation vaccines. The Company's mRNA platform can produce variant-matched vaccines on an accelerated time horizon, consistent with recent U.S. Food and Drug Administration (FDA) comments on the timing of potential strain selection for the fall booster season.

A recent announcement of positive interim results from the NEXTCove Phase 3 trial showed that mRNA-1283 elicited a higher immune response against both the Omicron BA.4/BA.5 and original virus strains of SARS-CoV-2 compared to mRNA-1273.222, Moderna's licensed COVID-19 vaccine. mRNA-1283 is designed to be refrigerator-stable and paves the way for a combination vaccine against influenza and COVID-19, mRNA-1083, enhancing the Company's overall respiratory portfolio. This is Moderna's fourth infectious disease vaccine program with Phase 3 data.

Respiratory Syncytial Virus (RSV)

RSV is the leading cause of respiratory illness in young children, and older adults are at increased risk relative to younger adults for severe outcomes. In addition to acute mortality and morbidity, RSV infection is associated with long-term sequelae such as asthma and impaired lung function in pediatric populations, and exacerbation of chronic obstructive pulmonary disease in older adults. Annually, there are approximately two million medically attended RSV infections and 58,000 to 80,000 hospitalizations in children younger than five years old in the U.S. In the U.S., each year there are up to 160,000 hospitalizations and 10,000 deaths in adults 65 years and older due to RSV. Across high-income countries in 2019, RSV caused an estimated 5.2 million cases, 470,000 hospitalizations and 33,000 in-hospital deaths in adults 60 years and older.

mRNA-1345

Moderna's RSV vaccine candidate, mRNA-1345, is in an ongoing Phase 2/3, randomized, observer-blind, placebo-controlled case-driven trial (ConquerRSV) in adults over 60 years of age. In this study, approximately 37,000 participants from 22 countries were randomized 1:1 to receive one dose of mRNA-1345 or placebo.

Based on positive data from the ConquerRSV trial, Moderna has filed for regulatory approvals for mRNA-1345 for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD) and acute respiratory disease (ARD) in adults over 60 years of age.

The trial met both its primary efficacy endpoints, with a vaccine efficacy (VE) of 83.7% (95.88% CI: 66.1%, 92.2%; p<0.0001) against RSV-LRTD as defined by two or more symptoms, and a VE of 82.4% (96.36% CI: 34.8%, 95.3%; p=0.0078) against RSV-LRTD defined by three or more symptoms. These data were published in the New England Journal of Medicine in December 2023.

A subsequent analysis from the ConquerRSV study with a longer median follow-up duration of 8.6 months (versus 3.7 months in the primary analysis), with a range of 15 days to 530 days, and including subjects from the Northern and Southern Hemispheres was recently presented at the RSVVW'24 conference. In this supplemental analysis, mRNA-1345 maintained durable efficacy, with sustained VE of 63.3% (95.88% CI: 48.7%, 73.7%) against RSV-LRTD including two or more symptoms. VE was 74.6% (95% CI: 50.7%, 86.9%) against RSV-LRTD with ≥2 symptoms, including shortness of breath and 63.0% (95% CI: 37.3%, 78.2%) against RSV-LRTD including three of more symptoms. The stringent statistical criterion of the study, a lower bound on the 95% CI of >20%, continued to be met for both endpoints.

mRNA-1345 has been granted Breakthrough Therapy designation by the FDA for the prevention of RSV-LRTD in adults over 60 years of age. The Company is awaiting regulatory approvals and the U.S. ACIP recommendation in 2024.

Indication expansion studies for mRNA-1345

mRNA-1345 has the potential to protect all vulnerable populations from RSV. Moderna has initiated multiple Phase 3 expansion studies in adults over 50 years of age to evaluate co-administration and revaccination. Additional trials (Phase 1 - Phase 3) have been initiated for high-risk adults, as well as maternal and pediatric populations. Interim data from these studies could be available as early as 2024.

Influenza (Flu)

Worldwide, influenza leads to 3-5 million severe cases of flu and 290,000-650,000 flu-related respiratory deaths annually. Two main types of influenza viruses (A and B) cause seasonal flu epidemics, and the influenza A viruses lead to most flu-related hospitalization in older adults.

The Company has several seasonal influenza vaccine candidates in clinical development. Moderna's seasonal flu vaccine, mRNA-1010, demonstrated consistently acceptable safety and tolerability across three Phase 3 trials. In the most recent Phase 3 trial (P303), which was designed to test the immunogenicity and safety of an optimized vaccine composition, mRNA-1010 met all immunogenicity primary endpoints, demonstrating higher antibody titers compared to a currently licensed standard-dose flu vaccine. In an older adult extension study of P303, mRNA-1010 is being studied against high dose Fluzone HD®; the trial is fully enrolled. The Company is in ongoing discussions with regulators and intends to file in 2024.

Combination Respiratory Vaccines

Moderna's combination vaccine candidates cover respiratory viruses associated with the largest disease burden in the category. The Phase 3 combination study of the Company's investigational combination vaccine against flu and COVID-19 (mRNA-1083) for adults aged 50 years and older is fully enrolled and data are expected in 2024. mRNA-1083 was granted Fast Track designation by the FDA in May 2023.

Commercial Updates

Respiratory viruses in addition to latent and other viruses represent large unmet or underserved medical needs, and the human and economic costs from these infectious diseases highlight the need for effective vaccines. To help address this need, Moderna expects multiple vaccine product launches in the next few years, each with significant addressable markets.

The 2024 global endemic COVID-19 vaccine market alone is estimated by Moderna to be approximately $10 billion. COVID-19 continues to show a high burden of disease, and while COVID-19 hospitalizations remain high relative to RSV and flu, the risks of Long COVID are also becoming better understood. Moderna is focused on improving education and awareness to increase vaccination rates as Long COVID data suggests even traditionally low-risk groups should be vaccinated. Moderna is also working with health authorities to align the timing of COVID-19 and flu vaccine launches to help improve public health.

For RSV, Moderna estimates the peak annual market to be approximately $10 billion. The Company expects a strong RSV vaccine launch into a large market in 2024. As the only mRNA investigational vaccine with positive Phase 3 data, Moderna's RSV vaccine candidate has a strong profile with consistently strong efficacy across vulnerable and older populations, a well-established safety and tolerability profile, and ease of administration with a ready-to-use, pre-filled syringe formulation, which could relieve some of the burden that falls on pharmacies during the fall vaccination season.

An interim analysis from an ongoing time and motion study evaluating differences in preparation time between a pre-filled syringe (PFS) presentation and vaccines that require reconstitution showed that a PFS presentation could relieve some of the burden that falls on pharmacies during the fall vaccination season. Results from this study suggest that pharmacies may be capable of preparing up to four times as many doses of PFS in an hour compared to vaccines requiring reconstitution.

Moderna estimates flu vaccines represent an approximately $7 billion market in 2024. The market is expected to grow with the rise of more effective vaccines and there is an opportunity to expand the market with next-generation premium flu vaccines as well as combination respiratory vaccines, adding increased value to the health ecosystem.

CMV is expected to be a $2-5 billion annual market. With no vaccine currently on the market and a potential vaccine launch in 2026, Moderna could be the first CMV vaccine in multi-billion-dollar latent vaccine market. In addition, EBV has the potential to address and reduce the burden and cost of EBV infection in multiple populations, while VZV provides the opportunity to enter a large and growing market, which could be $5-6 billion annually. The market for norovirus vaccines is similar to that of rotavirus in pediatrics with opportunity to expand into the adult population, and represents a $3-6 billion annual market.

Moderna's vaccine portfolio targets large addressable markets, with an estimated total addressable market (TAM) of $52 billon for Moderna infectious disease vaccines, which includes a respiratory vaccines TAM of more than $27 billion and a latent and other vaccines TAM of more than $25 billion.

Manufacturing

The Company's manufacturing innovation supports expanding commercialization of a diverse pipeline through efficiency and productivity gains. Its mRNA manufacturing platform enables benefits such as quality, speed, scale and cost efficiency across a footprint that broadly includes the manufacture of plasmid, mRNA, lipid nanoparticles, as well as fill/finish and quality control capabilities.

As the Company continues to build its footprint for the future, it is developing an agile global manufacturing network to meet commercial demand and support its growing pipeline. Pre-clinical through commercial manufacturing occurs at the Moderna Technology Center in Norwood, Massachusetts, which remains central to the Company's network. New facilities being constructed in Australia, Canada and the UK are expected to come online in 2025, and drug product capacity is achieved through a flexible contract manufacturing network. Additionally, the Company has purchased and started build-out of a manufacturing site in Marlborough, Massachusetts, to enable commercial scale of its individualized neoantigen therapy program.

By continuing to pioneer new technologies, including advanced robotics, applying AI and other digital solutions, and driving network and capital efficiency, Moderna's manufacturing network is expected to also drive more predictable cost of sales.

Research and Development Investment Strategy

Today's updates provide further evidence that Moderna's mRNA technology platform is working, and with a rate of success higher than industry standard. Looking ahead, research and development will continue to be the Company's top capital allocation priority.

As Moderna looks to create value through the research and development strategy for its vaccine portfolio, it is taking three prioritization parameters into consideration: pipeline advancement, revenue diversification and risk reduction. As part of its strategy, the funding options Moderna considers are self-funding, project financing and partnerships.

Moderna recently entered into a development and commercialization funding agreement with Blackstone Life Sciences to advance the Company's flu program. As part of the agreement, Blackstone will fund up to $750 million with a return based on cumulative commercial milestones and low-single digit royalties. Moderna expects to recognize the funding as a reduction in research and development expenses and will retain full rights and control of the Company's flu program. This funding does not result in any change to Moderna's 2024 research and development framework of approximately $4.5 billion.

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.


Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

INDICATION (U.S.)

SPIKEVAX (COVID-19 Vaccine, mRNA) is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older.

IMPORTANT SAFETY INFORMATION

  • Do not administer to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine.
  • Appropriate medical treatment to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of the vaccine.
  • Postmarketing data demonstrate increased risks of myocarditis and pericarditis, particularly within 7 days following the second dose. The observed risk is higher among males under 40 years of age than among females and older males. The observed risk is highest in males 18 through 24 years of age.
  • Syncope (fainting) may occur in association with administration of injectable vaccines. Procedures should be in place to avoid injury from fainting.
  • Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished response to the vaccine.
  • The vaccine may not protect all vaccine recipients.
  • Adverse reactions reported in clinical trials following administration of the vaccine include pain at the injection site, fatigue, headache, myalgia, arthralgia, chills, nausea/vomiting, axillary swelling/tenderness, fever, swelling at the injection site, and erythema at the injection site, and rash.
  • The vaccination provider is responsible for mandatory reporting of certain adverse events to the Vaccine Adverse Event Reporting System (VAERS) online at vaers.hhs.gov/reportevent.html or by calling 1-800-822-7967.
  • Please see the SPIKEVAX Full Prescribing Information. For information regarding authorized emergency uses of the Moderna COVID-19 Vaccine, please see the EUA Fact Sheet.

Spikevax® is a registered trademark of Moderna.
Fluzone® is a registered trademark of Sanofi Pasteur.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the advancement of Moderna's programs under clinical development; the timing for anticipated approvals of vaccine candidates; the efficacy, safety and tolerability of vaccine candidates; the total addressable markets for programs under development; the efficiencies and advantages of Moderna's mRNA platform; future capital allocation and financing efforts; and anticipated spending for R&D in 2024. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "could," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. ​

###

Moderna Contacts

Media:
Chris Ridley
Head, Global Media Relations
+1 617-800-3651
[email protected]

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
[email protected]

SOURCE: Moderna, Inc.

View the original press release on accesswire.com

Source link

Tags:
27Mar

Stanislaus County health officials watch for signs of fast-spreading COVID-19 variant

Posted by: admin Categories: PULMONARY DISEASES
Comments Off on Stanislaus County health officials watch for signs of fast-spreading COVID-19 variant

A COVID-19 subvariant being watched by health experts most recently accounted for more than 60% of coronavirus cases in the western region of the United States.

In Stanislaus County, public health officials don’t have many tools for local tracking of COVID-19 variants, including the closely watched JN.1, an offshoot of the BA.2.86 omicron variant.

So far, it’s not the variant with the highest or fastest-growing proportion of cases in Central California.

But the JN.1 variant is driving an overall increase of COVID-19 infections, according to a Johns Hopkins Bloomberg School of Public Health blog this month. It evades immunity like BA.2.86 but also has mutations allowing it to spread person-to-person more easily.

The Centers for Disease Control and Prevention said in December there’s no evidence that JN.1 causes more severe illness or poses more risk than other variants of the virus causing COVID-19 illness. But with repeated infections, there always is a risk of suffering “long COVID” symptoms for months.

The symptoms associated with JN.1 are virtually the same as other omicron strains. It may start with a sore throat, leading to congestion, runny nose, cough, muscle aches and chills. Severe COVID symptoms requiring emergency medical attention include trouble breathing, persistent chest pain, confusion or inability to stay awake.

The CDC said updated vaccines for COVID-19 should provide protection against the different variants, including JN.1.

Hospitals in Stanislaus County are feeling the impact of the COVID-19 and seasonal flu circulating in the community at the same time, as total cases have been increasing.

Kamlesh Kaur, a county health educator, said admissions for COVID-19 were increasing until just recently. The latest count was 23 patients hospitalized, including three receiving intensive care.

The county’s test positivity, as of Jan. 11, was 7.98%, which was lower than the statewide average. The wastewater testing for evidence of COVID on Jan. 6 represented a 14% decrease compared to the previous two weeks.

Source link

Tags:
27Mar

The best methods to improve ventilator reliability and accuracy

Posted by: admin Categories: PULMONARY DISEASES
Comments Off on The best methods to improve ventilator reliability and accuracy

Medical ventilators are advanced air circulation systems engineered to facilitate breathing for a patient unable to do so independently. A variety of medical ventilators are available for use in different medical environments.

The best methods to improve ventilator reliability and accuracy

Image Credit: Superior Sensor Technology

A variety of medical ventilators are available for use in different environments:

  • Transport ventilators: First responders, ambulance services, and helicopter transport use transport ventilators. In emergencies, these electronic ventilators supply breathing assistance until a patient is transferred to a hospital. They are more compact and robust than their hospital counterparts and offer diverse power source options. 
  • Intensive care (ICU) ventilators: Large ventilators are located in hospitals and powered by AC electricity. They are used in the surgical and ICU areas and offer comprehensive features and capabilities. 
  • Critical care ventilators: Although lacking some of the features of ICU ventilators, critical care ventilators are equipped with enough functionality to manage emergencies and long-term critical ventilation situations. These ventilators tend to be found in hospitals’ emergency and specialized care units.
  • Home ventilators: These smaller devices assist patients who cannot breathe independently after discharge. A home ventilator continues to support a patient’s breathing until they can do so without assistance.

Neonatal ventilators are medical ventilators designed explicitly for neonatal and infant patients. The key difference is that they are intended to provide lower and more precise rates of ventilation.

Modern medical ventilation systems are controlled electronically, with embedded processing that precisely regulates air pressure and flow according to each patient's specific requirements. These systems are considered to be life-critical because a system failure could cause severe patient harm.

Before the COVID-19 pandemic, medical ventilators were fundamental to hospital care. However, the demand for ventilators has risen substantially over the last few years.

Hospitals routinely use high-pressure ventilators, which are tank-based and built into the infrastructure. However, the current trend in medical ventilation is towards portable solutions, specifically low-pressure units. These mobile units are equipped with a miniaturized O2 tank or can function without one.

Ease of transport is a major advantage of these devices. They can provide increased mobility for the patient and be easily relocated when required.

These modern systems have a blower mechanism that produces the required air on demand instead of full-sized tanks. The blower operates like a standard fan, using blades to create airflow. The blades' noise is a challenge, and it must be addressed to guarantee accurate and efficient operation.

Examples of Low-Pressure Medical Ventilators

Figure 1. Examples of low-pressure medical ventilators. Image Credit: Superior Sensor Technology

Superior Sensor VN Series improves ventilator performance

A number of medical studies have suggested that approximately one-third of patients experience dyssynchrony during mechanical ventilation. This is when the ventilator does not match the patient’s breathing requirements.

This can result in increased respiratory work, lung damage, discomfort, extended ventilator reliance, and weaning difficulties. To improve synchrony, ventilators must respond faster to patient breathing demands and eliminate the impact of system noise.

Pressure sensors in ventilators, crucial for monitoring and controlling airflow, can be affected by system noise from internal blowers and external vibrations. Traditional systems often slow down response time by oversampling sensor data, further complicating the issue.

Designed specifically for medical ventilators, the VN Series by Superior Sensor uses an innovative oversampling technique that effectively eradicates all noise beyond the relevant band. This proprietary technology allows mechanical ventilators to use sensor outputs at their maximum speed, eliminating the requirement for oversampling sensor outputs and decreasing the system response time by as much as tenfold.

The series is made up of seven devices, each of which caters to a broad spectrum of system applications, ranging from flow measurement to inlet, inspiratory, expiratory, and barometric pressures. 

Advanced digital processing significantly reduces system-level noise interference. Additionally, the sensors boast 24-bit output resolution, improved filtering, remarkable zero stability, and are capable of supporting an update rate surpassing 1 kHz.

They have been meticulously designed to enhance system accuracy and reduce error rates. This proves especially advantageous for patients facing life-threatening respiratory conditions.

The table below highlights the uses of different sensors within the VN Series.

Table 1. VN Series product family. Source: Superior Sensor Technology

VN Series Product Family

The VN026CM and VN131CM offer extreme bandwidth resolution, enhancing the sensor’s effective resolution, amplifying the dynamic range, and reducing the noise floor by an additional 20 dB.

The VN026CM and VN131CM have the lowest noise floor and, for the first time, can offer manufacturers single-sensor solutions catering to numerous respiratory requirements for neonates and adults.

Comparing Extreme Resolution to Standard Resolution and Competitive Offerings

Graph 1. Comparing extreme resolution to standard resolution and competitive offerings. Image Credit: Superior Sensor Technology

The VN Series sensors have integrated additional features like advanced digital filtering and a three-mode pressure switch. These transform pressure sensors into sensing subsystems, increasing manufacturing efficiency and reliability.

Every VN Series sensor uses the same footprint and is pin-compatible with each other. The simplified PCB layouts allow manufacturers to easily interchange VN Series sensors for a variety of applications.

Conclusion

The VN Series employs cutting-edge digital signal processing and noise filtering methods to enhance medical ventilator performance. By facilitating rapid sensor data retrieval and eliminating interference, the sensors enable ventilators to adapt promptly and precisely to patient breathing patterns.

This heightened speed and accuracy, coupled with advanced functionalities such as three-mode pressure switching, can notably enhance patient-ventilator synchronization and minimize discomfort.

Offering industry-leading resolution and noise reduction within a standard footprint, the VN Series provides ventilator manufacturers with a flexible pressure-sensing solution to enhance system dependability and more effectively cater to the needs of critical care patients.

Major global ventilator manufacturers, like Vyaire, trust Superior Sensor Technology to supply their differential pressure sensors. 

About Superior Sensor TechnologyLogo

Superior Sensor Technology is an innovative, high technology company revolutionizing the high performance, cost driven pressure sensor market by developing integrative, highly intelligent solutions for industrial, HVAC and medical applications.

Our proprietary pressure sensor technology with advanced programmable software features enables customers to develop higher performing, more reliable equipment.

Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Source link

Tags:
27Mar

Cardiac Monitoring Devices Market Size to Worth USD 34.01 billion by 2030 with a 4.6% CAGR

Posted by: admin Categories: SPORTS & ATHLETICS
Comments Off on Cardiac Monitoring Devices Market Size to Worth USD 34.01 billion by 2030 with a 4.6% CAGR

A wearable heart rate monitor is an instance of a personal monitoring device. It allows for real-time heart rate monitoring. Wearable heart rate monitors come in wrist bands and chest straps. These are small and lightweight devices designed to work in harsh environments. Advanced features of heart rate monitors include activity, heart rate variation, breathing rate, and core temperature. The wrist band is a more popular heart rate monitoring device because it is comfortable and simple to use.

The Cardiac Monitoring Devices Market report is the most important research for who looks for complete information on the Cardiac Monitoring Devices market. The report covers all information on the global and regional markets including historic and future trends for market demand, size, trading, supply, competitors, and prices as well as global predominant vendor’s information. The forecast market information, SWOT analysis, Cardiac Monitoring Devices market scenario, and feasibility study are the vital aspects analyzed in this report.

The Cardiac Monitoring Devices Market is anticipated to grow from  USD 23.2 billion in 2024 to USD 34.01 billion by 2030, at a CAGR of 4.6% during the forecast period.

Top Leading Companies of Global Cardiac Monitoring Devices Market are:

Medtronic, Abbott, Boston Scientific Corporation, GE Healthcare, BIOTRONIK, and Koninklijke Philips N.V.

Get a free Sample Copy of this Report:

exactitudeconsultancy.com/reports…t-a-sample

The Cardiac Monitoring Devices Market segments and Market Data Break Down are illuminated below

Type Segment in Cardiac Monitoring Devices Market, 2019-2025, (in USD million)

ECG Devices

Resting ECG Devices

Stress ECG Devices

Holter Monitors

Implantable Loop Recorders

Mobile Cardiac Telemetry Devices

Cardiac Output Monitoring Devices

Event Monitors

Smart ECG Monitors

Type Segment in Cardiac Rhythm Management Devices Market, 2019-2025, (in USD million)

Defibrillators

Implantable Cardioverter Defibrillators

External Defibrillators

Pacemakers

Implantable Pacemakers

External Pacemakers

Cardiac Rhythm Management Devices Market End-User Segment, 2019-2025, (in USD million)

Hospitals & Clinics

Cardiac Centers

Ambulatory Surgery Centers

Other End Users

Wearable Heart Monitoring Devices Market Dynamics

Drivers

Rise in the number of geriatric and obese population

Because life expectancy has increased over time, more people are in their 60s and older. According to the United Nations Database on World Population Ageing 2020, there will be 1.5 billion elderly people worldwide by 2050, up from 727 million in 2020. Elderly people are more likely to sustain fall-related injuries, which can lead to a range of functional restrictions and a dependence on mobility aids. As a result, it is anticipated that the global geriatric population would grow dramatically, driving up the demand for patient handling and mobility equipment. The prevalence of obesity in the population is rising quickly.

In 2020, 39 million kids under the age of five will be overweight or obese.

Opportunities

Growing adoption rate of artificial intelligence and 5G

Furthermore, the increasing adoption of artificial intelligence and 5G will provide favourable opportunities for the wearable heart monitoring devices market growth. 5G can use artificial intelligence (AI) to determine a patient's potential diagnosis and treatments. Furthermore, AI can help healthcare systems predict which patients are likely to have postoperative complications, allowing for early intervention. Furthermore, the growing emphasis of manufacturers on the adoption of advanced technologies, as well as the increase in the number of emerging markets, will provide beneficial opportunities for the growth of the wearable heart monitoring devices market during the forecast period.

Regional Analysis for Cardiac Monitoring Devices Market:

  1. North American Market (USA, Canada, North America, Mexico),

  2. European Market (Germany, France, UK, Russia, Italy),

  3. Asia Pacific Market (China, Japan, South Korea, Asian Countries, India, Southeast Asia),

  4. South American Market (Brazil, Argentina ) , Colombia,.),

  5. Middle East and Africa Market (Saudi Peninsula, UAE, Egypt, Nigeria, South Africa)

Global Cardiac Monitoring Devices Market provides valuable insights such as: 

  • Nature of the competition in Global Cardiac Monitoring Devices Market

  • Key segments with largest share in Global Cardiac Monitoring Devices Market

  • Emerging technologies that can pave way for product innovation

  • Consumer purchasing trends related to the products and services in Global Cardiac Monitoring Devices Market

  • End-use industries expected to foster growth in the market

  • Impact of COVID-19 pandemic on manufacturing and production cycles in the Cardiac Monitoring Devices Market

  • Region-specific policy frameworks and regulatory guidelines

  • Unexplored geographical regions with lucrative opportunities for stakeholders in the market

Crucial Elements from the Table of Contents of Global Cardiac Monitoring Devices Market:

Chapter 1: Cardiac Monitoring Devices Market Overview
Chapter 2: Global Cardiac Monitoring Devices Market Competition, Profiles/Analysis, Strategies
Chapter 3: Global Cardiac Monitoring Devices Capacity, Production, Revenue (Value) by Region (2016-2021)
Chapter 4: Global Cardiac Monitoring Devices Supply (Production), Consumption, Export, Import by Region (2016-2021)
Chapter 5: Global Cardiac Monitoring Devices Market Regional Highlights
Chapter 6: Industrial Chain, Sourcing Strategy, and Downstream Buyers
Chapter 7: Marketing Strategy Analysis, Distributors/Traders
Chapter 8: Market Effect Factors Analysis
Chapter 9: Market Decisions for the present scenario
Chapter 10: Global Cardiac Monitoring Devices Market Forecast (2024-2030)
Chapter 11: Case Studies
Chapter 12: Research Findings and Conclusion

Explore Full Report With Detailed TOC Here:

exactitudeconsultancy.com/reports…es-market/

Key questions answered in the report:

  • What is the growth potential of the Cardiac Monitoring Devices market?

  • What growth opportunities might arise in the Cardiac Monitoring Devices industry in the years to come?

  • What are the most significant challenges that the Cardiac Monitoring Devices market could face in the future?

  • What are the key technologies and Cardiac Monitoring Devices Market trends shaping the Cardiac Monitoring Devices Market?

  • What Should Be Entry Strategies, Countermeasures to Economic Impact, and Marketing Channels for Cardiac Monitoring Devices Industry?

Report –

  • Analyzing the outlook of the market with the recent trends and SWOT analysis.

  • Market dynamics scenario, along with growth opportunities of the market in the years to come.

  • Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and non-economic aspects.

  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.

  • Market value (USD Million) and volume (Units Million) data for each segment and sub-segment

  • Competitive landscape involving the market share of major players, along with the new projects and -strategies adopted by players in the past years.

Finally, the Cardiac Monitoring Devices Market report is the believable source for gaining the market research that will exponentially accelerate your business. The report gives the principle locale, economic situations with the item value, benefit, limit, generation, supply, request, and market development rate and figure, and so on. The Cardiac Monitoring Devices industry report additionally presents a new task SWOT examination, speculation attainability investigation, and venture return investigation.

Following are a few examples of the customization requests:

The Cardiac Monitoring Devices market is a diverse and constantly evolving industry, with a wide range of customization requests from clients. Here are a few examples of the most common customization requests:

  1. Personalization of products: Many clients in the Cardiac Monitoring Devices market request custom-made products that cater to their specific needs and preferences. This can include everything from customized packaging and branding to unique product features and sizes.

  2. Customized packaging: Packaging is a key component of any product, and clients in the Cardiac Monitoring Devices market often request customized packaging that reflects their brand identity and aesthetic. This can include custom labels, stickers, and even custom boxes with unique shapes and designs.

  3. Custom product formulations: Clients in the Cardiac Monitoring Devices market often request custom product formulations that are tailored to their specific needs.

  4. Exclusive collaborations: Many brands in the Cardiac Monitoring Devices market collaborate with influencers or celebrities to create limited-edition products or collections. These collaborations often feature exclusive packaging, unique product formulations, and special branding.

Additional paid Services: -

  • Client will get one free update on the purchase of Corporate User License.

  • Quarterly Industry Update for 1 Year at 40% of the report cost per update.

  • One dedicated research analyst allocated to the client.

  • Fast Query resolution within 48 hours.

  • Industry Newsletter at USD 100 per month per issue.

Get More:  exactitudeconsultancy.com/primary-research/

Thank you for your interest in the Cardiac Monitoring Devices Market research publications; you can also get individual chapters or regional/country report versions such as Germany, France, China, Latin America, GCC, North America, Europe or Asia.

News From

Exactitude Consultancy.Exactitude Consultancy.
Category: Industry Reports & Market Analysis Profile: Exactitude Consultancy is a market research &amp; consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
What we aim is to provide a holistic picture of the market taking into account all the possible market drivers.
With an aim to cover ...

This email address is being protected from spambots. You need JavaScript enabled to view it.

Source link

Tags:
27Mar

New study reveals who was more vulnerable to

Posted by: admin Categories: SPORTS & ATHLETICS
Comments Off on New study reveals who was more vulnerable to

Anne-Marie Fors Connolly

image: 

Anne-Marie Fors Connolly, Assoc Prof MD PhD
Department of Clinical Microbiology, Umeå university


view more 

Credit: Hans Karlsson

People with post-COVID syndrome (PCS) following the COVID-19 infection often suffer from intense fatigue and dyspnea. This is what emerges from a new Nordic study led by Umeå University and recently published in the BMJ Public Health journal. High blood pressure also appears to be a risk factor for PCS diagnosis, according to the study’s findings.

"These scientific results are an important step in better understanding PCS. By identifying key factors, we can improve diagnosis, adapt care and pave the way for research into more effective treatments," says Anne-Marie Fors Connolly, MD PhD, Assoc Prof, clinical researcher at Umeå University and the study's senior author.

The study analyzed data from over one million people in Sweden who tested positive for COVID-19 during the period from February 2020 to May 2021. Of these, 1.5 percent, just over 16,000 people, were diagnosed with PCS after the main COVID-19 infection. They were diagnosed in both outpatient and inpatient care, which provided large datasets for the researchers to examine the clinical footprint of PCS. The researchers conducted an in-depth study of PCS symptoms in individuals who required ongoing healthcare three months after the COVID-19 infection.

The researchers found that the most common symptoms associated with PCS were dyspnoea (difficulty breathing), malaise, and fatigue, as well as abnormal lung examination findings. People with PCS were more likely to have hypertension and high blood pressure compared to both people who had undergone COVID-19 infection without later being diagnosed with PCS and compared to people who had not contracted COVID-19 at all. This indicates a vulnerability in people with high blood pressure. Notably, dyspnoea emerged as a new symptom for the majority of those diagnosed with PCS, underscoring its significance in PCS symptomatology and how clinicians diagnose PCS.

In determining which COVID-19 patients were diagnosed with post-COVID syndrome, a strong correlation was observed with the severity of illness during the early stages of infection. In particular, individuals who required mechanical ventilation for breathing assistance were at high risk of being diagnosed with PCS after recovering from the COVID-19 infection.

The study's comprehensive approach, leveraging data from multiple nationwide registries, provides a unique overview of PCS and valuable insights for healthcare providers. The results underline the importance of future studies on the underlying causes and potential treatments of PCS.

"Our study elucidates symptomatology and how clinicians diagnose PCS. Understanding the clinical and demographic characteristics of PCS is crucial to develop targeted care strategies for those suffering from long-term effects of COVID-19," says Dr. Hanna Ollila, FIMM-EMBL Group Leader at the University of Helsinki.

The study is developed within the EU-funded research project NeuroCOV and is additionally funded by the Swedish Research Council and Academy of Finland. Led by Umeå University, it involves institutions in four Nordic countries, including the Swedish and Finnish nodes of the Nordic EMBL Partnership for Molecular Medicine, the Laboratory for Molecular Infection Medicine Sweden (MIMS) and the Institute for Molecular Medicine Finland (FIMM) at University of Helsinki.

Journal

BMJ Public Health

Method of Research

Data/statistical analysis

Subject of Research

People

Article Title

How do clinicians use post-COVID syndrome diagnosis? Analysis of clinical features in a Swedish COVID-19 cohort with 18 months’ follow-up: a national observational cohort and matched cohort study

Article Publication Date

26-Mar-2024

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Source link

Tags:
26Mar

Flu, RSV and COVID cases are set to rise soon, so when should you get vaccinated?

Posted by: admin Categories: PULMONARY DISEASES
Comments Off on Flu, RSV and COVID cases are set to rise soon, so when should you get vaccinated?

Cooler weather is on our doorstep and it's bringing some very unwanted house guests — their names are COVID, influenza and RSV.

Some experts are predicting a particularly bad flu season and there's concern vaccine uptake will remain low and, in turn, hospitalisations will increase.

There's also talk of the dreaded "flurona".

Past experience shows infections will ramp up soon, usually around late April. Some vaccine guidelines have also recently changed.

Let's unpack the latest advice.

Influenza

The 2023 flu season was particularly long, but the 2024 season could be even worse, says Michael Clements, vice president and rural chair of the Royal Australian College of GPs.

"We've been isolated in the past [during the pandemic] so there isn't a lot of herd immunity.

"International travel is full steam ahead and we typically import our influenza from the northern hemisphere."

However, he says a higher rate of infections can also reflect the fact people can now buy at-home testing kits and find out if they have influenza or RSV.

"So in the past we may never have even known they had influenza."

Father wiping toddler daughters nose

Children aged between six months to five years old are at high risk of developing severe influenza symptoms.(Getty Images: MoMo Productions)

Christopher Blyth, a paediatric infectious diseases professor with the University of Western Australia, says every influenza season is different so it's hard to make many predictions.

"But what I will say is a significant number of children will be hospitalised with influenza this year, like every year."

Last year, children between the ages of five and nine had the highest influenza notification rates, and the number of deaths in children under 16 was higher than in many pre-COVID pandemic years. 

"The bulk of children hospitalised are in good health, they just aren't vaccinated," says Professor Blyth, who's the director of the Wesfarmers Centre of Vaccines and Infectious Diseases at the Telethon Kids Institute.

According to the latest government data, influenza cases are higher than expected for this time of year (around 1.7 times greater than the same time last year).

Your immunisation guide:

Annual influenza vaccination is recommended for everyone over six months of age.

The following groups can receive their vaccine for free under the National Immunisation Program (NIP):

  • children aged between six months and five years
  • those over 65
  • Aboriginal and Torres Strait Islander people
  • anyone pregnant
  • those with medical conditions that increase their risk of severe influenza

The Queensland government also recently announced it would pay the cost of the flu vaccine for all residents not covered by the NIP. 

Dr Clements says pharmacies are starting to see vaccines trickle in, but the government stock is not due until around early April.

"I know some people are really keen but we actually want to tell them it's OK to wait, as it takes a month or so to get peak effect from the vaccine and it does taper off at between four to six months."

Professor Blyth says getting a vaccine in April will mean you're protected when infections start ramping up in May and still be covered for the peak, which is typically in August.

A COVID vaccination being administered to a young child.

A flu vaccine is needed every year as influenza virus strains mutate.(ABC News: Herlyn Kaur)

Vaccination coverage last year was low, with around 32 per cent of the population vaccinated.

Dr Clements says it's "heartbreaking" to see people suffer from something preventable and he particularly wants to see more pregnant women and young children vaccinated this year.

He says the higher the vaccine uptake, the lower the peak of infections. This will make the entire community safer, including those who aren't vaccinated.

"Because there's always people who can't get the vaccine or have it but it doesn't work."

The vaccine's effectiveness rate is between 40 to 60 per cent.

RSV

Respiratory syncytial virus (RSV) infections are common and can be very disruptive.

"Most parents can give a really good history of being awake at night worried about the wet cough their child has," Dr Clements says.

"For the elderly, it's often RSV that triggers the pneumonia that kills them."

Source link

Tags:
26Mar

I’ve tested positive for COVID-19. Can I still go to the emergency room?

Posted by: admin Categories: PULMONARY DISEASES
Comments Off on I’ve tested positive for COVID-19. Can I still go to the emergency room?

Officials with Health P.E.I. say wait times at the emergency room can be long, but people who are positive for COVID-19 who experience severe symptoms should seek care at the hospital if they feel they need it. (Steve Bruce/CBC - image credit)

Officials with Health P.E.I. say wait times at the emergency room can be long, but people who are positive for COVID-19 who experience severe symptoms should seek care at the hospital if they feel they need it. (Steve Bruce/CBC - image credit)

One woman on P.E.I. who tested positive for COVID-19 says she's left with questions after spending hours in an Island emergency room without seeing a doctor.

Kendal Winegarden said when she arrived at the hospital, staff questioned her about why she would come when she knew she was positive for COVID-19 – and now she's asking where people who are positive for the virus should turn when symptoms get worse?

Winegarden found out she had tested positive for COVID-19 last Monday. She had a number of symptoms – a cough, sore throat and fatigue. But by Thursday morning those symptoms began to get worse.

"I was short of breath, I couldn't do anything and I was feeling tightness in my chest," Winegarden said.

Even something like taking a shower left her unable to catch her breath, she said. Winegarden is immune-compromised and lives in rural P.E.I. and said she was worried about being stuck without care if her symptoms were to get much worse.

She called 811 and the province's COVID-19 line with no luck speaking to anyone. When her breathing hadn't improved she called the Queen Elizabeth Hospital in Charlottetown and was told to come into the emergency department right away.

But when she got there, staff asked her why she would come when she knew she had COVID-19.

Submitted by Kendal WinegardenSubmitted by Kendal Winegarden

Submitted by Kendal Winegarden

"I said 'Because I was told to and because I had trouble breathing.' And her response was, 'Well we try to keep people with COVID out of the hospital' and I said, 'Well I wouldn't be here if I didn't feel like maybe I should be checked out.'"

Winegarden said the triage nurse checked her vitals and she was told to sit in a COVID-19 waiting area. She said she waited there for more than six hours and was told the hospital was very busy and it could be morning before she was seen by a physician. At that point it was only 6 p.m., so Winegarden said she gave up and went home.

She said her fever broke the following morning and she's now feeling much better. But the experience left her with one pressing question:

"What are people supposed to do, really? If you have COVID symptoms and you're positive, you do the right thing, you isolate … what are people who have COVID symptoms worsening supposed to do?"

If you're feeling awful, come to the ER

Dr. Tom Kaul, co-chief of the QEH emergency department, said the evening Winegarden came into the hospital was a very busy one, which is common.

But her decision to come to the emergency room was the right one.

"If you're feeling awful, and you feel like trying to get from your couch to the bathroom renders you very short of breath, then absolutely you should come in for assessment and I hope that assessment will be reassuring," Kaul said.

Dr. Kaul said he knows wait times in the emergency department can be long. He was working the night Winegarden came to seek care.

ZoomZoom

Zoom

In the past few weeks, he said about 20 per cent of people visiting the QEH emergency department leave without seeing a physician. He said that's because of the ER's limited capacity, caused by a combination of staffing shortages and high number of people seeking care.

Something COVID-19 hasn't helped.

But, Dr. Kaul said anyone coming to the ER should be reassured that an assessment by a triage nurse will tell you whether you need to be admitted to hospital.

"I would certainly put forward how valuable the assessments by our nursing staff are because your vital signs and things we do readily get at the door — listen to your chest, and an assessment of your breathing — are really critical and replicate what we're going to do as physicians as well," he said.

"That triage assessment is really valuable and — if reassuring to the triage nurse — should hopefully be reassuring to patients as well."

Cough and fever clinics also an option

Winegarden said she's feeling better now and, after isolating with her family, she hopes they can all put their experience with COVID-19 behind them.

Dr. Kaul said the goal is to see every patient who comes into the ER for care and while there can be long waits, that shouldn't deter people from coming to the hospital if they are worried about their condition — whether they've been diagnosed with COVID-19 or not.

He said people with COVID-19 can also visit the province's cough and fever clinics if they're worried about their symptoms.

Source link

Tags:
26Mar

SARS-CoV-2, influenza A/B and respiratory syncytial virus positivity and association with influenza-like illness and self-reported symptoms, over the 2022/23 winter season in the UK: a longitudinal surveillance cohort | BMC Medicine

Posted by: admin Categories: PULMONARY DISEASES
Comments Off on SARS-CoV-2, influenza A/B and respiratory syncytial virus positivity and association with influenza-like illness and self-reported symptoms, over the 2022/23 winter season in the UK: a longitudinal surveillance cohort | BMC Medicine

  • Moss JWE, Davidson C, Mattock R, Gibbons I, Mealing S, Carroll S. Quantifying the direct secondary health care cost of seasonal influenza in England. BMC Public Health. 2020;20(1):1464.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Shi T, Denouel A, Tietjen AK, Campbell I, Moran E, Li X, et al. Global disease burden estimates of respiratory syncytial virus-associated acute respiratory infection in older adults in 2015: a systematic review and meta-analysis. J Infect Dis. 2020;222(Supplement 7):S577–83.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Hammond A, Kim JJ, Sadler H, Vandemaele K. Influenza surveillance systems using traditional and alternative sources of data: a scoping review. Influenza Other Respir Viruses. 2022;16(6):965–74.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Brooks-Pollock E, Tilston N, Edmunds WJ, Eames KT. Using an online survey of healthcare-seeking behaviour to estimate the magnitude and severity of the 2009 H1N1v influenza epidemic in England. BMC Infect Dis. 2011;11:68.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Fragaszy EB, Warren-Gash C, Wang L, Copas A, Dukes O, Edmunds WJ, et al. Cohort profile: the flu watch study. Int J Epidemiol. 2017;46(2):e18.

    PubMed 

    Google Scholar     

  • Adler AJ, Eames KT, Funk S, Edmunds WJ. Incidence and risk factors for influenza-like-illness in the UK: online surveillance using Flusurvey. BMC Infect Dis. 2014;14(1):1–8.

    Article 

    Google Scholar     

  • Yang TU, Cheong HJ, Song JY, Lee JS, Wie S-H, Kim YK, et al. Age- and influenza activity-stratified case definitions of influenza-like illness: experience from hospital-based influenza surveillance in South Korea. PLoS One. 2014;9(1):e84873.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Casalegno JS, Eibach D, Valette M, Enouf V, Daviaud I, Behillil S, et al. Performance of influenza case definitions for influenza community surveillance: based on the French influenza surveillance network GROG, 2009–2014. Euro Surveill. 2017;22(14):30504.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Domínguez À, Soldevila N, Torner N, Martínez A, Godoy P, Rius C, et al. Usefulness of clinical definitions of influenza for public health surveillance purposes. Viruses. 2020;12(1):95.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Aguilera JF, Paget WJ, Mosnier A, Heijnen ML, Uphoff H, van der Velden J, et al. Heterogeneous case definitions used for the surveillance of influenza in Europe. Eur J Epidemiol. 2003;18(8):751–4.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Jiang L, Lee VJ, Lim WY, Chen MI, Chen Y, Tan L, et al. Performance of case definitions for influenza surveillance. Eurosurveillance. 2015;20(22):21145.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Davis W, Duque J, Huang QS, Olson N, Grant CC, Newbern EC, et al. Sensitivity and specificity of surveillance case definitions in detection of influenza and respiratory syncytial virus among hospitalized patients, New Zealand, 2012–2016. J Infect. 2022;84(2):216–26.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Souty C, Masse S, Valette M, Behillil S, Bonmarin I, Pino C, et al. Baseline characteristics and clinical symptoms related to respiratory viruses identified among patients presenting with influenza-like illness in primary care. Clin Microbiol Infect. 2019;25(9):1147–53.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Heinonen S, Peltola V, Silvennoinen H, Vahlberg T, Heikkinen T. Signs and symptoms predicting influenza in children: a matched case–control analysis of prospectively collected clinical data. Eur J Clin Microbiol Infect Dis. 2012;31(7):1569–74.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Kalimeri K, Delfino M, Cattuto C, Perrotta D, Colizza V, Guerrisi C, et al. Unsupervised extraction of epidemic syndromes from participatory influenza surveillance self-reported symptoms. PLoS Comput Biol. 2019;15(4):e1006173.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Ma X, Conrad T, Alchikh M, Reiche J, Schweiger B, Rath B. Can we distinguish respiratory viral infections based on clinical features? A prospective pediatric cohort compared to systematic literature review. Rev Med Virol. 2018;28(5):e1997.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Barry MA, Arinal F, Talla C, Hedible BG, Sarr FD, Ba IO, et al. Performance of case definitions and clinical predictors for influenza surveillance among patients followed in a rural cohort in Senegal. BMC Infect Dis. 2021;21(1):31.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Soldevila N, Toledo D, Martínez A, Godoy P, Torner N, Rius C, et al. Does knowing the influenza epidemic threshold has been reached influence the performance of influenza case definitions? PLoS One. 2022;17(7):e0270740.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Belongia EA, Simpson MD, King JP, Sundaram ME, Kelley NS, Osterholm MT, McLean HQ. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016;16(8):942–51.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Vihta KD, Pouwels KB, Peto TEA, Pritchard E, Eyre DW, House T, et al. Symptoms and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) positivity in the general population in the United Kingdom. Clin Infect Dis. 2022;75(1):e329–37.

    Article 
    PubMed 

    Google Scholar     

  • Pouwels KB, House T, Pritchard E, Robotham JV, Birrell PJ, Gelman A, et al. Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS coronavirus infection survey. Lancet Public Health. 2021;6(1):e30–8.

    Article 
    PubMed 

    Google Scholar     

  • Office for National Statistics. Influenza and other respiratory viruses pilot study: Coronavirus (COVID-19) Infection Survey, UK. 2023. Available from: www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/articles/influenzaandotherrespiratoryvirusespilotstudycoronaviruscovid19infectionsurveyuk/october2022tofebruary2023.

  • Nuffield Department of Medicine. University of Oxford. Questionnaires. 2023. Available from: www.ndm.ox.ac.uk/covid-19/covid-19-infection-survey/case-record-forms.

  • Fitzner J, Qasmieh S, Mounts AW, Alexander B, Besselaar T, Briand S, et al. Revision of clinical case definitions: influenza-like illness and severe acute respiratory infection. Bull World Health Organ. 2018;96(2):122–8.

    Article 
    PubMed 

    Google Scholar     

  • Commission E. Commission Implementing Decision (EU) 2018/945 of 22 June 2018 on the communicable diseases and related special health issues to be covered by epidemiological surveillance as well as relevant case definitions. OJEU. 2018;61:170.


    Google Scholar     

  • Wood S. Package ‘mgcv’. 2023. Available from: cran.r-project.org/web/packages/mgcv/mgcv.pdf.

  • Wood SN. Thin plate regression splines. J R Stat Soc Ser B Stat Methodol. 2003;65(1):95–114.

    Article 

    Google Scholar     

  • Gelman A, Little T. Poststratification into many categories using hierarchical logistic regression. Surv Methodol. 1997;23(2):127–35.


    Google Scholar     

  • Goldstein E, Dushoff J, Ma J, Plotkin JB, Earn DJ, Lipsitch M. Reconstructing influenza incidence by deconvolution of daily mortality time series. Proc Natl Acad Sci U S A. 2009;106(51):21825–9.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Goldstein E, Cowling BJ, Aiello AE, Takahashi S, King G, Lu Y, Lipsitch M. Estimating incidence curves of several infections using symptom surveillance data. PLoS One. 2011;6(8):e23380.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Camacho A, Eames K, Adler A, Funk S, Edmunds J. Estimation of the quality of life effect of seasonal influenza infection in the UK with the internet-based Flusurvey cohort: an observational cohort study. Lancet. 2013;382:S8.

    Article 

    Google Scholar     

  • Seran H, Jie Z, Jakob J, Anika S, Jack LB, Kieran JM, et al. Onset and window of SARS-CoV-2 infectiousness and temporal correlation with symptom onset: a prospective, longitudinal, community cohort study. Lancet Respir Med. 2022;10(11):1061–73.

    Article 

    Google Scholar     

  • Blake J. Personal communication. 2023.


    Google Scholar     

  • Vos LM, Bruyndonckx R, Zuithoff NPA, Little P, Oosterheert JJ, Broekhuizen BDL, et al. Lower respiratory tract infection in the community: associations between viral aetiology and illness course. Clin Microbiol Infect. 2021;27(1):96–104.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Munywoki PK, Koech DC, Agoti CN, Kibirige N, Kipkoech J, Cane PA, et al. Influence of age, severity of infection, and co-infection on the duration of respiratory syncytial virus (RSV) shedding. Epidemiol Infect. 2015;143(4):804–12.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Fielding JE, Kelly HA, Mercer GN, Glass K. Systematic review of influenza A(H1N1)pdm09 virus shedding: duration is affected by severity, but not age. Influenza Other Respir Viruses. 2014;8(2):142–50.

    Article 
    PubMed 

    Google Scholar     

  • Cane J, Street T, Sanderson N, Swann J, Vaughan A, Morgan M, et al. Nanopore whole genome sequencing of community and hospital influenza in the United Kingdom, 2022-2023. Poster session session presented at: ECCMID 2023. 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 2023 Apr 15-18; Copenhagen, Denmark.

  • UK Health Security Agency. Surviellance of influenza and other seasonal respiratory viruses in the UK, winter 2022 to 2023. 2023. www.gov.uk/government/statistics/annual-flu-reports/surveillance-of-influenza-and-other-seasonal-respiratory-viruses-in-the-uk-winter-2022-to-2023.

  • UK Health Security Agency. Weekly national Influenza and COVID-19 surveillance report: Week 5 report (up to week 4 data). 2023. www.gov.uk/government/statistics/national-flu-and-covid-19-surveillance-reports-2022-to-2023-season.

  • Guy R, Henderson KL, Coelho J, Hughes H, Mason EL, Gerver SM, et al. Increase in invasive group A streptococcal infection notifications, England, 2022. Euro Surveill. 2023;28(1):2200942.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Yang J, Huang P, Shie S, Yang S, Tsao K, Wu T, et al. Predictive symptoms and signs of laboratory-confirmed influenza: a prospective surveillance study of two metropolitan areas in Taiwan. Medicine (Baltimore). 2015;94(44):e1952.

  • Sáez-López E, Pechirra P, Costa I, Cristóvão P, Conde P, Machado A, et al. Performance of surveillance case definitions for respiratory syncytial virus infections through the sentinel influenza surveillance system, Portugal, 2010 to 2018. Euro Surveill. 2019;24(45):1900140.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Colosia A, Costello J, McQuarrie K, Kato K, Bertzos K. Systematic literature review of the signs and symptoms of respiratory syncytial virus. Influenza Other Respir Viruses. 2023;17(2):e13100.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Korsten K, Adriaenssens N, Coenen S, Butler CC, Verheij TJM, Bont LJ, Wildenbeest JG. World Health Organization influenza-like illness underestimates the burden of respiratory syncytial virus infection in community-dwelling older adults. J Infect Dis. 2022;226(Suppl 1):S71–8.

    Article 
    PubMed 

    Google Scholar     

  • Rha B, Dahl RM, Moyes J, Binder AM, Tempia S, Walaza S, et al. Performance of surveillance case definitions in detecting respiratory syncytial virus infection among young children hospitalized with severe respiratory illness-South Africa, 2009–2014. J Pediatric Infect Dis Soc. 2019;8(4):325–33.

    Article 
    PubMed 

    Google Scholar     

  • Subissi L, Bossuyt N, Reynders M, Gérard M, Dauby N, Bourgeois M, et al. Capturing respiratory syncytial virus season in Belgium using the influenza severe acute respiratory infection surveillance network, season 2018/19. Euro Surveill. 2020;25(39):1900627.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Office for National Statistics. Prevalence of symptoms and impact of respiratory infections, UK. 2023. www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofsymptomsandimpactofrespiratoryinfectionsuk/10july2023.

  • Gimma A, Munday JD, Wong KLM, Coletti P, Zandvoort KV, Prem K, et al. Changes in social contacts in England during the COVID-19 pandemic between March 2020 and March 2021 as measured by the CoMix survey: A repeated cross-sectional study. PLOS Med. 2022;19(3):e1003907.

  • Bi Q, Dickerman BA, McLean HQ, Martin ET, Gaglani M, Wernli KJ, et al. Evaluating reduced effectiveness after repeat influenza vaccination while accounting for confounding by recent infection and within-season waning. medRxiv. 2023:2023.03.12.23287173.

  • The Francis Crick Institute. Vaccine composition 2022. Available from: www.crick.ac.uk/research/platforms-and-facilities/worldwide-influenza-centre/vaccine-composition.

  • UK Health Security Agency. Surveillance of influenza and other seasonal respiratory viruses in winter 2021 to 2022. 2023. www.gov.uk/government/statistics/annual-flu-reports/surveillance-of-influenza-and-other-seasonal-respiratory-viruses-in-winter-2021-to-2022.

  • Office for National Statistics. Coronavirus (COVID-19) infection survey: technical data. 2022. www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/covid19infectionsurveytechnicaldata.

  • Office for National Statistics. Coronavirus (COVID-19) infection survey quality report. 2022. www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/methodologies/coronaviruscovid19infectionsurveyqualityreportaugust20222022.

  • Office for National Statistics. Coronavirus (COVID-19) infection survey quality report. 2022. www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/methodologies/coronaviruscovid19infectionsurveyqualityreportdecember20222022.

  • Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK. 2022. www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1september2022#impact-of-moving-to-remote-data-collection2022.

  • Hay JA, Kissler SM, Fauver JR, Mack C, Tai CG, Samant RM, et al. Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and infection rebound: a retrospective cohort study. eLife. 2022;11:e81849. citation = eLife 2022;11 e.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Office for National Statistics. Coronavirus (COVID-19) infection survey: quality and methodology information (QMI). 2023. Available from: www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/methodologies/coronaviruscovid19infectionsurveyqmi.

    • Source link

    Tags:
    26Mar

    Bizarre COVID Conspiracies Linked To High Stress Levels: Rutgers Study

    Posted by: admin Categories: ANXIETY MANAGEMENT
    Comments Off on Bizarre COVID Conspiracies Linked To High Stress Levels: Rutgers Study

    But according to researchers at Rutgers University-Newark, other “bogus beliefs” aren’t so amusing in hindsight: such as curing COVID-19 by ingesting household cleaners such as bleach.

    As America looks back on the fourth anniversary of the pandemic, Rutgers researchers recently attempted to answer a tricky question: Why do some people fall for conspiracy theories – and others don’t?

    The short answer? “Stress,” researchers said.

    In 2020 – during the heart of the pandemic – psychologists Kent Harber and Valeria Vila wanted to know why “wildly erroneous beliefs, unfounded suspicions and rejection of scientific information and public health advice” was becoming so rampant.

    “Why were some people denying legitimate facts that could help them cope with this deadly pandemic?” they asked.

    Harber and Vila ended up conducting two studies involving 750 adults across the United States. The participants reported on their daily life stress, chronic stress, depression and their COVID-specific stress. They also took a COVID Beliefs Survey, which included conspiracy theories as well as factual statements “based on science and public health guidelines.”

    For example, participants were asked if COVID was a hoax designed to control the stock market, or serve as divine punishment for a sinful world. They were also surveyed on whether COVID could be cured by teas and essential oils. Meanwhile, they were also asked for their opinions on factual statements, such as the efficacy of handwashing or the prospect that the pandemic could continue for many months.

    The results, which were recently published in the "Journal of Social and Political Psychology," found that people with high levels of emotional distress – even distress unrelated to COVID – were more likely to embrace supernatural explanations for the pandemic, conspiracy theories and false remedies.

    Highly distressed people are also more likely to deny COVID-related facts, such as the respiratory risk that the virus presented or the benefits of basic hygiene, the researchers said.

    Harber and Vila found that different types of stress produced different outcomes. People with general-life distress, such as relationship tensions, financial worries and depression, more strongly endorsed false beliefs and denied facts. They were also more likely to engage in survivalist activities, such as buying guns and planning escape routes – which was readily reinforced by other conspiracy believers.

    Researchers noted that people with “COVID-specific anxieties” were more likely to accept facts and follow recommendations from health experts, but still clung to bogus beliefs.

    And when the pandemic hit, the confusion from everyone – including experts – only made things worse, Harber said.

    “COVID was highly contagious, it could have long-lasting effects, and in some cases, it was fatal,” the Rutgers-Newark professor recalled. “And it seemed to come out of the blue. Experts didn’t know its cause, whether it was natural or human made, and the medical establishment and even the federal government initially issued contradictory advice.”

    Fantastical beliefs, conspiracies and bogus cures can become seductively attractive when people feel afraid, confused or powerless, Harber added.

    “As humans, we have a basic fight or flight response to threats,” he said. “You can’t hide from or beat up a virus. However, you can direct your fears against unpopular shadowy figures and groups who are supposedly conspiring in some nefarious ways.”

    Luckily, there is a cure for the “infodemic,” the Rutgers researchers said: Hope.

    As part of the studies, Harber and Vila also asked participants to report on their self-esteem and levels of social support, as well as their “hope, optimism and sense of purpose.” These psychological resources had an inoculating effect, they found – people with more of these resources were resistant to bogus beliefs and were less likely to deny COVID facts.

    Ironically, some of the steps for weathering the pandemic – such as social distancing and school and work closures – deprived people of the very resources that would help them cope, Harber said.

    Since the threat of another pandemic or catastrophe always looms in the future, it’s crucial that psychological coping mechanisms be considered in crisis situations, Harber contends.

    “Having policies and practices that allow people to maintain their resources should be part of the coordinated response,” he suggested. “You have to address the psyche, not only the body.”

    Send local news tips and correction requests to [email protected]. Learn more about advertising on Patch here. Find out how to post announcements or events to your local Patch site. Don’t forget to visit the Patch Newark Facebook page.

    Source link

    Tags:
    26Mar

    3 more COVID deaths in New Brunswick, 4 youth among flu hospitalizations

    Posted by: admin Categories: PULMONARY DISEASES
    Comments Off on 3 more COVID deaths in New Brunswick, 4 youth among flu hospitalizations

    Since the beginning of the respiratory season on Aug. 27, 86 New Brunswickers have died from COVID, there have been 1,396 hospitalizations and 91 intensive care admissions. (CBC - image credit)

    Since the beginning of the respiratory season on Aug. 27, 86 New Brunswickers have died from COVID, there have been 1,396 hospitalizations and 91 intensive care admissions. (CBC - image credit)

    Three more New Brunswickers have died from COVID-19, while no new influenza deaths have been reported, and hospitalizations for both viruses have decreased, updated data from the province Tuesday shows.

    A child under four, and three youth aged five to 19 are among those hospitalized by the flu between March 10 and March 16, according to the Respiratory Watch report.

    "COVID-19 activity remains moderate; some indicators (number of cases, percent positivity, and hospitalizations) decreased slightly during the current reporting period," it says.

    Influenza activity "slightly decreased" during the reporting week.

    Of the three people who died, one was aged 45 to 64 and the other two were aged 65 or older.

    Their deaths raise the province's pandemic death toll to at least 1,022. The actual total is unclear because the Department of Health counts only people who die in hospital as COVID deaths.

    Fifteen people were hospitalized because of COVID or for something else and later tested positive, down from 21 in the previous report.

    One person required intensive care, unchanged.

    Of those hospitalized, three are aged 45 to 64, and 12 are aged 65 or older, including the one in ICU.

    6 outbreaks, 40 new cases

    Six lab-confirmed COVID outbreaks have been declared, the same number as the previous week. Four are in nursing homes and two are in facilities described only as "other."

    Forty new cases of COVID have been confirmed through PCR (polymerase chain reaction) lab tests, down from 60.

    The positivity rate — or the percentage of lab tests performed that produced a positive result — is three per cent, down from five.

    428 more vaccines administered

    About 400 New Brunswickers rolled up their sleeves to get a COVID-19 vaccine in the past week, after the Department of Health urged anyone who has not received a vaccine or had a COVID infection within the last six months to get a shot soon to ensure they are protected and to ensure they meet the recommended six-month interval to get a fall vaccine.

    A total of 147,677 XBB.1.5 vaccines have been administered since Oct. 4, figures from the department show.

    Spring COVID-19 vaccine boosters will be available April 2 through June 15 for New Brunswickers considered most at risk of severe illness, the department announced last week. This includes people aged 65 or older, residents of nursing homes and adult residential facilities and immunocompromised people aged six months or older.

    Comirnaty, the Pfizer-BioNTech COVID-19 vaccine (booster). September, 2023. Comirnaty, the Pfizer-BioNTech COVID-19 vaccine (booster). September, 2023.

    Comirnaty, the Pfizer-BioNTech COVID-19 vaccine (booster). September, 2023.

    Although spring boosters won't be administered until April 2, bookings for appointments opened up on Monday. (Joe Burbank/The Associated Press)

    Eligible New Brunswickers can book appointments now, either online, by calling 1-833-437-1424 or by contacting a participating pharmacy.

    People who do not meet the eligibility guidelines but received a fall or winter dose as part of the current vaccination campaign, which began Oct. 16, "are considered fully up to date, and do not require another vaccine this spring," department spokesperson Sean Hatchard said.

    Flu sends 13 to hospital, 2 to ICU

    The flu sent 13 people to hospital between March 10 and March 15, down from 23 in the previous report.

    Two of them required intensive care, up from none.

    In addition to the four youth hospitalized, there were also two people aged 20 to 44, and seven people aged 65 or older, including the two in ICU, the report shows.

    A hospital room with a vacant bed.A hospital room with a vacant bed.

    A hospital room with a vacant bed.

    The flu has hospitalized 506 people since the respiratory season began on Aug. 27, 47 of whom required intensive care, according to the Respiratory Watch report. (CBC)

    Ninety-nine new cases of the flu were confirmed through lab tests, down from 145, and the positivity rate is nine per cent, down from 12.

    The breakdown of new cases includes 64 influenza B and 35 influenza A.

    There have now been 2,998 cases reported since the respiratory season began on Aug. 27

    Three lab-confirmed influenza outbreaks have been declared — one in a nursing home and two in "other facilities." A week ago, none were reported.

    There was also one "influenza-like illness" outbreak reported at a school, up from none. No other details are provided, but school outbreaks are based on 10 per cent absenteeism because of influenza-like illness symptoms, according to the report.

    As of Tuesday, a total of 222,394 New Brunswickers have been vaccinated against the flu this season, up from 221,808 a week ago, the Department of Health said.

    Vitalité releases monthly COVID update

    Vitalité Health Network posted its monthly COVID-19 update Tuesday. It shows 15 COVID-positive health-care workers are off sick, as of Saturday, down from 33 in the February report.

    There are six hospitalized COVID patients, up from five. None require intensive care, unchanged.

    The number of Vitalité health-care workers off the job because of COVID has dropped nearly 55 per cent to 15 in the past month, data released Tuesday shows.The number of Vitalité health-care workers off the job because of COVID has dropped nearly 55 per cent to 15 in the past month, data released Tuesday shows.

    The number of Vitalité health-care workers off the job because of COVID has dropped nearly 55 per cent to 15 in the past month, data released Tuesday shows.

    The number of Vitalité health-care workers off the job because of COVID has dropped nearly 55 per cent to 15 in the past month, data released Tuesday shows. (CBC)

    Vitalité's COVID outbreaks page hasn't been updated since March 21. At that time, there was one outbreak on Unit 200 at the Veterans' Health Centre in the Moncton region.

    A month ago, three hospitals each had one unit with an outbreak.

    Horizon Health Network has not yet updated its COVID dashboard.

    Source link

    Tags: